Immuno-oncology Assays Market by Component (Consumables (Cytotoxicity Assays, MOA-Reflective Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors, Functional Assays, Custom, Others), Software Platform (Immunoassay, PCR, NGS, Flow Cytometry, Others)) by Technology (2D, 3D) by Technology (Natural Killer Cells, Macrophages, Dendritic Cells, Neutrophils, Fibroblasts, Others) by Application (Screen and Develop Antibodies, Small Molecules, Cellular Therapies (Chimeric Antigen Receptor T Cells (CAR-T), ADCC, ADCP, T Cell Redirection, Adoptive T Cell Therapy, Others) by Targets (PD-1, SIRPα, CTLA4, OX40, ICOS, Others) by Indication (Lung Cancer, Colorectal Cancer, Melanoma, Bladder Cancer, Other Cancers) by Usage (Research Solutions (Tumor Microenvironment and Immune Composition, Tumor Mutational Burden and Neoantigens, Cancer Microbiome Research, Immunotherapy Research Publications, Others) Others)); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2020 - 2028
Industry Trends
Global immuno-oncology assays market was valued at US$ 3172.40 million in 2019 and is expected to reach US$ 9517.40 million by 2028, growing at a CAGR of 13.1% over the forecast period.
Immuno-oncology assays are a next-generation sequencing technology that provides automated immune and tumour cell dynamic measurements in real time. Biological processes driving the immune response to cancer can be studied with the aid of this assays. This assay helps preserve cell health and morphology and provides continuous analysis in real time. Factors such as the growing acceptance of targeted therapy over conventional therapy and increasing demand for mAbs are primarily driving the growth of this sector. Immuno-oncology research requires the use of multiple immunology tests that are used to monitor the relationship between immune cells and cancer cells. There is a tremendous opportunity for the human body's immune system to kill tumour cells, causing no toxicity to normal cells. In addition, the immune system also has the potential to prevent cancer recurrence.
Amongst diseases, cancer will boost the growth of the market over the forecast period. In addition, increasing targeted therapy adoption is boosting the growth of the market. In order to measure the concentration of therapeutic antibodies, anti-drug antibodies and soluble protein biomarkers immune-oncology assays are used. The market growth of assays increases as the popularity of targeted therapy increases.
The key factor in increasing market growth is increasing healthcare expenditure, increasing cancer prevalence, increasing patient preference for immunotherapies and immunodiagnostics due to side effects of radiation and chemotherapy and technological advances in the immune-oncology assay. However, the rising unfavourable regulatory and reimbursement scenario and the increased amount of capital investments are the main factors that will hinder market growth and will further challenge the growth of the market for immuno-oncology assays in the forecast period. The production of immuno-oncology assays has several challenges and requires specialist teams and experienced investigators. High costs and time required for manufacturing are also associated with the production of immuno-oncology assays. These variables are expected to hamper market growth over the forecast period.
During the forecast period, new product launches are expected to propel the growth of the immuno-oncology market. Roche Diagnostics, for example, launched the new VENTANA HER2 Dual ISH DNA Probe Cocktail assay in April 2019 to identify the biomarker of human epidermal growth factor receptor 2 (HER2) in breast and gastric cancers. In addition, key market players are focused on the launch of new immune-oncology assays, which are expected to drive the growth of the market for immune oncology assays. The growth of the global immuno-oncology assay market is driven by increased research and development activities for cancer treatment and the increase in the use of personalized medicines across the globe. Due to the reduction in test rates and the delay in cancer diagnosis, demand for immuno-oncology assays is expected to decrease during the Covid-19 pandemic. The repurposing of laboratory resources to provide Covid-19 research has impacted the capacity of laboratories involved in oncology testing, resulting in a decrease in the testing rate.
Component Insights
Based on component the immuno-oncology assay market is segmented into consumables and software platform. The consumables segment accounted for the major share in the market over the forecast period. This segment is also expected to register the highest CAGR during the forecast period. Major factors driving the growth of the segment is the availability of a wide range of reagents and kits, increased use of reagents in various clinical oncology therapies, increased research into cancer immunotherapy biomarkers and their drug development applications, and convenient access to a wide range of reagents.
Technology Insights
Based on technology the market is segmented into 2D and 3D technologies. The 3D technology will see a huge growth over the forecast period. Research institutes are adopting 3D based models as it gives more predictive data as to how the therapy will be performed which is augmenting the growth of the market over the years.
Cell Types Insights
In the cell type segment natural killer cells segment will see a considerable growth over the forecast period. In immunotherapeutic growth, the ability of natural killer cells to target and remove tumors is gaining new interest. Due to their cytotoxic function and possible tumor destroying activity, NK cells are an appealing target for therapies. In order to eliminate tumour formation, scientists are now shifting their attention towards these cells.
Application Insights
In application the screen and develop antibodies segment will see a significant growth over the period, researchers are engaged in the development of new antibodies for the treatment of cancer. Moreover, increasing demand for newer techniques in order to treat cancer is gaining momentum in the world and for that purpose the spending of government as well as private organizations towards the development of new techniques is getting traction which will boost the market for immune-oncology assays over the forecast period.
Targets Insights
In target the PD-1 segment will see a huge growth over the forecast period. The PD-1 ligand is a vital molecular target and testing patients for tumour cell PD-1 expression may lead to better clinical outcomes if they are selected for treatment. This factor will boost the growth of the segment over the period.
Indication Insights
Based on indication, the immuno-oncology assays market is segmented into lung cancer, colorectal cancer, melanoma, bladder cancer and other cancers. The lung cancer segment is expected to be the fastest-growing segment during the forecast period, due to increase in the number of patients with lung cancer major players in the market are targeting this segment. There is an increase in prevalence of immune-oncology research for lung cancer which will boost the growth of the market over the forecast period.
Usage Insights
On the basis of usage the immuno-oncology assays market is segmented into research solutions and others. The research solution segment dominated the market over the forecast period, this segment also exhibits a highest CAGR over the forecast period. The main factors driving market growth is the growing popularity of cancer microbiome research and clinical trials and the advent of cancer immunotherapy.
Regional Insights
It is expected that North America and Europe will be dominant regions in the market for immune-oncology assays. In these areas, well-established health care infrastructure and public and private sector support for research and development are expected to fuel the demand for immuno-oncology tests. In North America, adoption of technologically advanced devices and ongoing clinical trials in cancer therapy are expected to drive the market. This will boost the growth of techniques like immune-oncology assays to treat cancer patients in this region.
During the forecast period, Asia Pacific is expected to record a significant growth rate. The growth of this region is driven by factors such as a growing number of CROs in the region, increasing understanding of early cancer detection, and shifting the focus of manufacturers and suppliers from developed economies to emerging economies such as India and China. Increased funding from governing bodies and the private sector to develop successful and novel cancer therapeutics is expected to drive the region's growth. In addition, high cancer incidence in the Asia Pacific region is expected to present substantial opportunities for players operating in the market for immuno-oncology assays.
Immuno-oncology Assays Market Revenue & Forecast, (US$ Million), 2020 – 2028
Competitive Landscape
The report provides both, qualitative and quantitative research immuno-oncology assays market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
The major players operating in the market include Agilent, BioAgilytix, Charles River Laboratories, Creative Biolabs, Eurofins DiscoverX Products, Explicyte Immuno-Oncology, Illumina, Inc., Svar Life Science, Thermo Fisher Scientific and other market participants.
Immuno-oncology Assays Market:
- By Component
- Consumables
- Cytotoxicity Assays
- MOA-Reflective Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
- Functional Assays
- Custom
- Others
- Software Platform
- Immunoassay
- PCR
- NGS
- Flow Cytometry
- Others
- Consumables
- By Technology
- 2D
- 3D
- By Cell Types
- Natural Killer Cells
- Macrophages
- Dendritic Cells
- Neutrophils
- Fibroblasts
- Others
- By Application
- Screen and Develop Antibodies
- Small Molecules
- Cellular Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
- ADCC
- ADCP
- T Cell Redirection
- Adoptive T Cell Therapy
- Others
- By Targets
- PD-1
- SIRPα
- CTLA4
- OX40
- ICOS
- Others
- By Indication
- Lung Cancer
- Colorectal Cancer
- Melanoma
- Bladder Cancer
- Other Cancers
- By Usage
- Research Solutions
- Tumor Microenvironment and Immune Composition
- Tumor Mutational Burden and Neoantigens
- Cancer Microbiome Research
- Immunotherapy Research Publications
- Others
- Others
- Research Solutions
- By Geography
- North America
- U.S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1. Market
Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2018
1.2.2. Base
Year: 2019
1.2.3. Forecast
Years: 2020 – 2028
2. Key Target
Audiences
3. Research
Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations
and Insights from AMI’s Perspective**
5. Holistic
Overview of Immuno Oncology Assays Market
6. Market
Synopsis: Immuno Oncology Assays Market
7. Immuno
Oncology Assays Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Immuno Oncology Assays Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Immuno Oncology Assays Market
7.6. Porter’s Five Force Analysis
7.7. Impact of
Covid-19 on Immuno Oncology Assays Market
8. Global
Immuno Oncology Assays Market Analysis and Forecasts, 2020 – 2028
8.1. Overview
8.1.1. Global
Immuno Oncology Assays Market Revenue (US$ Mn)
8.2. Global
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Component
8.2.1. Consumables
(Definition, Market Estimation and Penetration, 2015 – 2019, Market Estimation
(2015 – 2019), Market Forecast (2020 – 2028), Compound Annual Growth Rate
(CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East
and Africa, Latin America) and Information on Cytotoxicity Assays,
MOA-Reflective Functional Assays for Co-Stimulatory and Inhibitory Checkpoint
Receptors, Functional Assays, Custom, Others)
8.2.1.1. Cytotoxicity
Assays
8.2.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
8.2.1.3. Functional
Assays
8.2.1.4. Custom
8.2.1.5. Others
8.2.2. Software
Platform (Definition, Market Estimation and Penetration, 2015 – 2019, Market
Estimation (2015 – 2019), Market Forecast (2020 – 2028), Compound Annual Growth
Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle
East and Africa, Latin America) and Information on Immunoassay, PCR, NGS, Flow
Cytometry, Others)
8.2.2.1. Immunoassay
8.2.2.2. PCR
8.2.2.3. NGS
8.2.2.4. Flow
Cytometry
8.2.2.5. Others
8.3. Key
Segment for Channeling Investments
8.3.1. By
Component
9. Global
Immuno Oncology Assays Market Analysis and Forecasts, 2020 – 2028
9.1. Overview
9.2. Global
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Technology
9.2.1. 2D
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2015 – 2019
9.2.1.3. Market
Forecast, 2020 – 2028
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2015 – 2019
9.2.1.5.1.2. Market
Forecast, 2020 – 2028
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 – 2019
9.2.1.5.2.2. Market
Forecast, 2020 – 2028
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2015 – 2019
9.2.1.5.3.2. Market
Forecast, 2020 – 2028
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 – 2019
9.2.1.5.4.2. Market
Forecast, 2020 – 2028
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2015 – 2019
9.2.1.5.5.2. Market
Forecast, 2020 – 2028
9.2.2. 3D
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2015 – 2019
9.2.2.3. Market
Forecast, 2020 – 2028
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2015 – 2019
9.2.2.5.1.2. Market
Forecast, 2020 – 2028
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 – 2019
9.2.2.5.2.2. Market
Forecast, 2020 – 2028
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2015 – 2019
9.2.2.5.3.2. Market
Forecast, 2020 – 2028
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 – 2019
9.2.2.5.4.2. Market
Forecast, 2020 – 2028
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2015 – 2019
9.2.2.5.5.2. Market
Forecast, 2020 – 2028
9.3. Key
Segment for Channeling Investments
9.3.1. By
Technology
10. Global
Immuno Oncology Assays Market Analysis and Forecasts, 2020 – 2028
10.1. Overview
10.2. Global
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell Types
10.2.1. Natural
Killer Cells
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2015 – 2019
10.2.1.3. Market
Forecast, 2020 – 2028
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2015 – 2019
10.2.1.5.1.2. Market
Forecast, 2020 – 2028
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 – 2019
10.2.1.5.2.2. Market
Forecast, 2020 – 2028
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2015 – 2019
10.2.1.5.3.2. Market
Forecast, 2020 – 2028
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 – 2019
10.2.1.5.4.2. Market
Forecast, 2020 – 2028
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2015 – 2019
10.2.1.5.5.2. Market
Forecast, 2020 – 2028
10.2.2. Macrophages
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2015 – 2019
10.2.2.3. Market
Forecast, 2020 – 2028
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2015 – 2019
10.2.2.5.1.2. Market
Forecast, 2020 – 2028
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 – 2019
10.2.2.5.2.2. Market
Forecast, 2020 – 2028
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2015 – 2019
10.2.2.5.3.2. Market
Forecast, 2020 – 2028
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 – 2019
10.2.2.5.4.2. Market
Forecast, 2020 – 2028
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2015 – 2019
10.2.2.5.5.2. Market
Forecast, 2020 – 2028
10.2.3. Dendritic
Cells
10.2.3.1. Definition
10.2.3.2. Market
Estimation and Penetration, 2015 – 2019
10.2.3.3. Market
Forecast, 2020 – 2028
10.2.3.4. Compound
Annual Growth Rate (CAGR)
10.2.3.5. Regional
Bifurcation
10.2.3.5.1. North
America
10.2.3.5.1.1. Market
Estimation, 2015 – 2019
10.2.3.5.1.2. Market
Forecast, 2020 – 2028
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 – 2019
10.2.3.5.2.2. Market
Forecast, 2020 – 2028
10.2.3.5.3. Asia
Pacific
10.2.3.5.3.1. Market
Estimation, 2015 – 2019
10.2.3.5.3.2. Market
Forecast, 2020 – 2028
10.2.3.5.4. Middle
East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 – 2019
10.2.3.5.4.2. Market
Forecast, 2020 – 2028
10.2.3.5.5. Latin
America
10.2.3.5.5.1. Market
Estimation, 2015 – 2019
10.2.3.5.5.2. Market
Forecast, 2020 – 2028
10.2.4. Neutrophils
10.2.4.1. Definition
10.2.4.2. Market
Estimation and Penetration, 2015 – 2019
10.2.4.3. Market
Forecast, 2020 – 2028
10.2.4.4. Compound
Annual Growth Rate (CAGR)
10.2.4.5. Regional
Bifurcation
10.2.4.5.1. North
America
10.2.4.5.1.1. Market
Estimation, 2015 – 2019
10.2.4.5.1.2. Market
Forecast, 2020 – 2028
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 – 2019
10.2.4.5.2.2. Market
Forecast, 2020 – 2028
10.2.4.5.3. Asia
Pacific
10.2.4.5.3.1. Market
Estimation, 2015 – 2019
10.2.4.5.3.2. Market
Forecast, 2020 – 2028
10.2.4.5.4. Middle
East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 – 2019
10.2.4.5.4.2. Market
Forecast, 2020 – 2028
10.2.4.5.5. Latin
America
10.2.4.5.5.1. Market
Estimation, 2015 – 2019
10.2.4.5.5.2. Market
Forecast, 2020 – 2028
10.2.5. Fibroblasts
10.2.5.1. Definition
10.2.5.2. Market
Estimation and Penetration, 2015 – 2019
10.2.5.3. Market
Forecast, 2020 – 2028
10.2.5.4. Compound
Annual Growth Rate (CAGR)
10.2.5.5. Regional
Bifurcation
10.2.5.5.1. North
America
10.2.5.5.1.1. Market
Estimation, 2015 – 2019
10.2.5.5.1.2. Market
Forecast, 2020 – 2028
10.2.5.5.2. Europe
10.2.5.5.2.1. Market
Estimation, 2015 – 2019
10.2.5.5.2.2. Market
Forecast, 2020 – 2028
10.2.5.5.3. Asia
Pacific
10.2.5.5.3.1. Market
Estimation, 2015 – 2019
10.2.5.5.3.2. Market
Forecast, 2020 – 2028
10.2.5.5.4. Middle
East and Africa
10.2.5.5.4.1. Market
Estimation, 2015 – 2019
10.2.5.5.4.2. Market
Forecast, 2020 – 2028
10.2.5.5.5. Latin
America
10.2.5.5.5.1. Market
Estimation, 2015 – 2019
10.2.5.5.5.2. Market
Forecast, 2020 – 2028
10.2.6. Others
10.2.6.1. Definition
10.2.6.2. Market
Estimation and Penetration, 2015 – 2019
10.2.6.3. Market
Forecast, 2020 – 2028
10.2.6.4. Compound
Annual Growth Rate (CAGR)
10.2.6.5. Regional
Bifurcation
10.2.6.5.1. North
America
10.2.6.5.1.1. Market
Estimation, 2015 – 2019
10.2.6.5.1.2. Market
Forecast, 2020 – 2028
10.2.6.5.2. Europe
10.2.6.5.2.1. Market
Estimation, 2015 – 2019
10.2.6.5.2.2. Market
Forecast, 2020 – 2028
10.2.6.5.3. Asia
Pacific
10.2.6.5.3.1. Market
Estimation, 2015 – 2019
10.2.6.5.3.2. Market
Forecast, 2020 – 2028
10.2.6.5.4. Middle
East and Africa
10.2.6.5.4.1. Market
Estimation, 2015 – 2019
10.2.6.5.4.2. Market
Forecast, 2020 – 2028
10.2.6.5.5. Latin
America
10.2.6.5.5.1. Market
Estimation, 2015 – 2019
10.2.6.5.5.2. Market
Forecast, 2020 – 2028
10.3. Key
Segment for Channeling Investments
10.3.1. By Cell
Types
11. Global
Immuno Oncology Assays Market Analysis and Forecasts, 2020 – 2028
11.1. Overview
11.2. Global
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Application
11.2.1. Screen
and Develop Antibodies
11.2.1.1. Definition
11.2.1.2. Market
Estimation and Penetration, 2015 – 2019
11.2.1.3. Market
Forecast, 2020 – 2028
11.2.1.4. Compound
Annual Growth Rate (CAGR)
11.2.1.5. Regional
Bifurcation
11.2.1.5.1. North
America
11.2.1.5.1.1. Market
Estimation, 2015 – 2019
11.2.1.5.1.2. Market
Forecast, 2020 – 2028
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 – 2019
11.2.1.5.2.2. Market
Forecast, 2020 – 2028
11.2.1.5.3. Asia
Pacific
11.2.1.5.3.1. Market
Estimation, 2015 – 2019
11.2.1.5.3.2. Market
Forecast, 2020 – 2028
11.2.1.5.4. Middle
East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 – 2019
11.2.1.5.4.2. Market
Forecast, 2020 – 2028
11.2.1.5.5. Latin
America
11.2.1.5.5.1. Market
Estimation, 2015 – 2019
11.2.1.5.5.2. Market
Forecast, 2020 – 2028
11.2.2. Small
Molecules
11.2.2.1. Definition
11.2.2.2. Market
Estimation and Penetration, 2015 – 2019
11.2.2.3. Market
Forecast, 2020 – 2028
11.2.2.4. Compound
Annual Growth Rate (CAGR)
11.2.2.5. Regional
Bifurcation
11.2.2.5.1. North
America
11.2.2.5.1.1. Market
Estimation, 2015 – 2019
11.2.2.5.1.2. Market
Forecast, 2020 – 2028
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 – 2019
11.2.2.5.2.2. Market
Forecast, 2020 – 2028
11.2.2.5.3. Asia
Pacific
11.2.2.5.3.1. Market
Estimation, 2015 – 2019
11.2.2.5.3.2. Market
Forecast, 2020 – 2028
11.2.2.5.4. Middle
East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 – 2019
11.2.2.5.4.2. Market
Forecast, 2020 – 2028
11.2.2.5.5. Latin
America
11.2.2.5.5.1. Market
Estimation, 2015 – 2019
11.2.2.5.5.2. Market
Forecast, 2020 – 2028
11.2.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
11.2.3.1. Definition
11.2.3.2. Market
Estimation and Penetration, 2015 – 2019
11.2.3.3. Market
Forecast, 2020 – 2028
11.2.3.4. Compound
Annual Growth Rate (CAGR)
11.2.3.5. Regional
Bifurcation
11.2.3.5.1. North
America
11.2.3.5.1.1. Market
Estimation, 2015 – 2019
11.2.3.5.1.2. Market
Forecast, 2020 – 2028
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2015 – 2019
11.2.3.5.2.2. Market
Forecast, 2020 – 2028
11.2.3.5.3. Asia
Pacific
11.2.3.5.3.1. Market
Estimation, 2015 – 2019
11.2.3.5.3.2. Market
Forecast, 2020 – 2028
11.2.3.5.4. Middle
East and Africa
11.2.3.5.4.1. Market
Estimation, 2015 – 2019
11.2.3.5.4.2. Market
Forecast, 2020 – 2028
11.2.3.5.5. Latin
America
11.2.3.5.5.1. Market
Estimation, 2015 – 2019
11.2.3.5.5.2. Market
Forecast, 2020 – 2028
11.2.4. ADCC
11.2.4.1. Definition
11.2.4.2. Market
Estimation and Penetration, 2015 – 2019
11.2.4.3. Market
Forecast, 2020 – 2028
11.2.4.4. Compound
Annual Growth Rate (CAGR)
11.2.4.5. Regional
Bifurcation
11.2.4.5.1. North
America
11.2.4.5.1.1. Market
Estimation, 2015 – 2019
11.2.4.5.1.2. Market
Forecast, 2020 – 2028
11.2.4.5.2. Europe
11.2.4.5.2.1. Market
Estimation, 2015 – 2019
11.2.4.5.2.2. Market
Forecast, 2020 – 2028
11.2.4.5.3. Asia
Pacific
11.2.4.5.3.1. Market
Estimation, 2015 – 2019
11.2.4.5.3.2. Market
Forecast, 2020 – 2028
11.2.4.5.4. Middle
East and Africa
11.2.4.5.4.1. Market
Estimation, 2015 – 2019
11.2.4.5.4.2. Market
Forecast, 2020 – 2028
11.2.4.5.5. Latin
America
11.2.4.5.5.1. Market
Estimation, 2015 – 2019
11.2.4.5.5.2. Market
Forecast, 2020 – 2028
11.2.5. ADCP
11.2.5.1. Definition
11.2.5.2. Market
Estimation and Penetration, 2015 – 2019
11.2.5.3. Market
Forecast, 2020 – 2028
11.2.5.4. Compound
Annual Growth Rate (CAGR)
11.2.5.5. Regional
Bifurcation
11.2.5.5.1. North
America
11.2.5.5.1.1. Market
Estimation, 2015 – 2019
11.2.5.5.1.2. Market
Forecast, 2020 – 2028
11.2.5.5.2. Europe
11.2.5.5.2.1. Market
Estimation, 2015 – 2019
11.2.5.5.2.2. Market
Forecast, 2020 – 2028
11.2.5.5.3. Asia
Pacific
11.2.5.5.3.1. Market
Estimation, 2015 – 2019
11.2.5.5.3.2. Market
Forecast, 2020 – 2028
11.2.5.5.4. Middle
East and Africa
11.2.5.5.4.1. Market
Estimation, 2015 – 2019
11.2.5.5.4.2. Market
Forecast, 2020 – 2028
11.2.5.5.5. Latin
America
11.2.5.5.5.1. Market
Estimation, 2015 – 2019
11.2.5.5.5.2. Market
Forecast, 2020 – 2028
11.2.6. T Cell
Redirection
11.2.6.1. Definition
11.2.6.2. Market
Estimation and Penetration, 2015 – 2019
11.2.6.3. Market
Forecast, 2020 – 2028
11.2.6.4. Compound
Annual Growth Rate (CAGR)
11.2.6.5. Regional
Bifurcation
11.2.6.5.1. North
America
11.2.6.5.1.1. Market
Estimation, 2015 – 2019
11.2.6.5.1.2. Market
Forecast, 2020 – 2028
11.2.6.5.2. Europe
11.2.6.5.2.1. Market
Estimation, 2015 – 2019
11.2.6.5.2.2. Market
Forecast, 2020 – 2028
11.2.6.5.3. Asia
Pacific
11.2.6.5.3.1. Market
Estimation, 2015 – 2019
11.2.6.5.3.2. Market
Forecast, 2020 – 2028
11.2.6.5.4. Middle
East and Africa
11.2.6.5.4.1. Market
Estimation, 2015 – 2019
11.2.6.5.4.2. Market
Forecast, 2020 – 2028
11.2.6.5.5. Latin
America
11.2.6.5.5.1. Market
Estimation, 2015 – 2019
11.2.6.5.5.2. Market
Forecast, 2020 – 2028
11.2.7. Adoptive
T Cell Therapy
11.2.7.1. Definition
11.2.7.2. Market
Estimation and Penetration, 2015 – 2019
11.2.7.3. Market
Forecast, 2020 – 2028
11.2.7.4. Compound
Annual Growth Rate (CAGR)
11.2.7.5. Regional
Bifurcation
11.2.7.5.1. North
America
11.2.7.5.1.1. Market
Estimation, 2015 – 2019
11.2.7.5.1.2. Market
Forecast, 2020 – 2028
11.2.7.5.2. Europe
11.2.7.5.2.1. Market
Estimation, 2015 – 2019
11.2.7.5.2.2. Market
Forecast, 2020 – 2028
11.2.7.5.3. Asia
Pacific
11.2.7.5.3.1. Market
Estimation, 2015 – 2019
11.2.7.5.3.2. Market
Forecast, 2020 – 2028
11.2.7.5.4. Middle
East and Africa
11.2.7.5.4.1. Market
Estimation, 2015 – 2019
11.2.7.5.4.2. Market
Forecast, 2020 – 2028
11.2.7.5.5. Latin
America
11.2.7.5.5.1. Market
Estimation, 2015 – 2019
11.2.7.5.5.2. Market
Forecast, 2020 – 2028
11.2.8. Others
11.2.8.1. Definition
11.2.8.2. Market
Estimation and Penetration, 2015 – 2019
11.2.8.3. Market
Forecast, 2020 – 2028
11.2.8.4. Compound
Annual Growth Rate (CAGR)
11.2.8.5. Regional
Bifurcation
11.2.8.5.1. North
America
11.2.8.5.1.1. Market
Estimation, 2015 – 2019
11.2.8.5.1.2. Market
Forecast, 2020 – 2028
11.2.8.5.2. Europe
11.2.8.5.2.1. Market
Estimation, 2015 – 2019
11.2.8.5.2.2. Market
Forecast, 2020 – 2028
11.2.8.5.3. Asia
Pacific
11.2.8.5.3.1. Market
Estimation, 2015 – 2019
11.2.8.5.3.2. Market
Forecast, 2020 – 2028
11.2.8.5.4. Middle
East and Africa
11.2.8.5.4.1. Market
Estimation, 2015 – 2019
11.2.8.5.4.2. Market
Forecast, 2020 – 2028
11.2.8.5.5. Latin
America
11.2.8.5.5.1. Market
Estimation, 2015 – 2019
11.2.8.5.5.2. Market
Forecast, 2020 – 2028
11.3. Key
Segment for Channeling Investments
11.3.1. By
Application
12. Global
Immuno Oncology Assays Market Analysis and Forecasts, 2020 – 2028
12.1. Overview
12.2. Global
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
12.2.1. PD-1
12.2.1.1. Definition
12.2.1.2. Market
Estimation and Penetration, 2015 – 2019
12.2.1.3. Market
Forecast, 2020 – 2028
12.2.1.4. Compound
Annual Growth Rate (CAGR)
12.2.1.5. Regional
Bifurcation
12.2.1.5.1. North
America
12.2.1.5.1.1. Market
Estimation, 2015 – 2019
12.2.1.5.1.2. Market
Forecast, 2020 – 2028
12.2.1.5.2. Europe
12.2.1.5.2.1. Market
Estimation, 2015 – 2019
12.2.1.5.2.2. Market
Forecast, 2020 – 2028
12.2.1.5.3. Asia
Pacific
12.2.1.5.3.1. Market
Estimation, 2015 – 2019
12.2.1.5.3.2. Market
Forecast, 2020 – 2028
12.2.1.5.4. Middle
East and Africa
12.2.1.5.4.1. Market
Estimation, 2015 – 2019
12.2.1.5.4.2. Market
Forecast, 2020 – 2028
12.2.1.5.5. Latin
America
12.2.1.5.5.1. Market
Estimation, 2015 – 2019
12.2.1.5.5.2. Market
Forecast, 2020 – 2028
12.2.2. SIRP?
12.2.2.1. Definition
12.2.2.2. Market
Estimation and Penetration, 2015 – 2019
12.2.2.3. Market
Forecast, 2020 – 2028
12.2.2.4. Compound
Annual Growth Rate (CAGR)
12.2.2.5. Regional
Bifurcation
12.2.2.5.1. North
America
12.2.2.5.1.1. Market
Estimation, 2015 – 2019
12.2.2.5.1.2. Market
Forecast, 2020 – 2028
12.2.2.5.2. Europe
12.2.2.5.2.1. Market
Estimation, 2015 – 2019
12.2.2.5.2.2. Market
Forecast, 2020 – 2028
12.2.2.5.3. Asia
Pacific
12.2.2.5.3.1. Market
Estimation, 2015 – 2019
12.2.2.5.3.2. Market
Forecast, 2020 – 2028
12.2.2.5.4. Middle
East and Africa
12.2.2.5.4.1. Market
Estimation, 2015 – 2019
12.2.2.5.4.2. Market
Forecast, 2020 – 2028
12.2.2.5.5. Latin
America
12.2.2.5.5.1. Market
Estimation, 2015 – 2019
12.2.2.5.5.2. Market
Forecast, 2020 – 2028
12.2.3. CTLA4
12.2.3.1. Definition
12.2.3.2. Market
Estimation and Penetration, 2015 – 2019
12.2.3.3. Market
Forecast, 2020 – 2028
12.2.3.4. Compound
Annual Growth Rate (CAGR)
12.2.3.5. Regional
Bifurcation
12.2.3.5.1. North
America
12.2.3.5.1.1. Market
Estimation, 2015 – 2019
12.2.3.5.1.2. Market
Forecast, 2020 – 2028
12.2.3.5.2. Europe
12.2.3.5.2.1. Market
Estimation, 2015 – 2019
12.2.3.5.2.2. Market
Forecast, 2020 – 2028
12.2.3.5.3. Asia
Pacific
12.2.3.5.3.1. Market
Estimation, 2015 – 2019
12.2.3.5.3.2. Market
Forecast, 2020 – 2028
12.2.3.5.4. Middle
East and Africa
12.2.3.5.4.1. Market
Estimation, 2015 – 2019
12.2.3.5.4.2. Market
Forecast, 2020 – 2028
12.2.3.5.5. Latin
America
12.2.3.5.5.1. Market
Estimation, 2015 – 2019
12.2.3.5.5.2. Market
Forecast, 2020 – 2028
12.2.4. OX40
12.2.4.1. Definition
12.2.4.2. Market
Estimation and Penetration, 2015 – 2019
12.2.4.3. Market
Forecast, 2020 – 2028
12.2.4.4. Compound
Annual Growth Rate (CAGR)
12.2.4.5. Regional
Bifurcation
12.2.4.5.1. North
America
12.2.4.5.1.1. Market
Estimation, 2015 – 2019
12.2.4.5.1.2. Market
Forecast, 2020 – 2028
12.2.4.5.2. Europe
12.2.4.5.2.1. Market
Estimation, 2015 – 2019
12.2.4.5.2.2. Market
Forecast, 2020 – 2028
12.2.4.5.3. Asia
Pacific
12.2.4.5.3.1. Market
Estimation, 2015 – 2019
12.2.4.5.3.2. Market
Forecast, 2020 – 2028
12.2.4.5.4. Middle
East and Africa
12.2.4.5.4.1. Market
Estimation, 2015 – 2019
12.2.4.5.4.2. Market
Forecast, 2020 – 2028
12.2.4.5.5. Latin
America
12.2.4.5.5.1. Market
Estimation, 2015 – 2019
12.2.4.5.5.2. Market
Forecast, 2020 – 2028
12.2.5. ICOS
12.2.5.1. Definition
12.2.5.2. Market
Estimation and Penetration, 2015 – 2019
12.2.5.3. Market
Forecast, 2020 – 2028
12.2.5.4. Compound
Annual Growth Rate (CAGR)
12.2.5.5. Regional
Bifurcation
12.2.5.5.1. North
America
12.2.5.5.1.1. Market
Estimation, 2015 – 2019
12.2.5.5.1.2. Market
Forecast, 2020 – 2028
12.2.5.5.2. Europe
12.2.5.5.2.1. Market
Estimation, 2015 – 2019
12.2.5.5.2.2. Market
Forecast, 2020 – 2028
12.2.5.5.3. Asia
Pacific
12.2.5.5.3.1. Market
Estimation, 2015 – 2019
12.2.5.5.3.2. Market
Forecast, 2020 – 2028
12.2.5.5.4. Middle
East and Africa
12.2.5.5.4.1. Market
Estimation, 2015 – 2019
12.2.5.5.4.2. Market
Forecast, 2020 – 2028
12.2.5.5.5. Latin
America
12.2.5.5.5.1. Market
Estimation, 2015 – 2019
12.2.5.5.5.2. Market
Forecast, 2020 – 2028
12.2.6. Others
12.2.6.1. Definition
12.2.6.2. Market
Estimation and Penetration, 2015 – 2019
12.2.6.3. Market
Forecast, 2020 – 2028
12.2.6.4. Compound
Annual Growth Rate (CAGR)
12.2.6.5. Regional
Bifurcation
12.2.6.5.1. North
America
12.2.6.5.1.1. Market
Estimation, 2015 – 2019
12.2.6.5.1.2. Market
Forecast, 2020 – 2028
12.2.6.5.2. Europe
12.2.6.5.2.1. Market
Estimation, 2015 – 2019
12.2.6.5.2.2. Market
Forecast, 2020 – 2028
12.2.6.5.3. Asia
Pacific
12.2.6.5.3.1. Market
Estimation, 2015 – 2019
12.2.6.5.3.2. Market
Forecast, 2020 – 2028
12.2.6.5.4. Middle
East and Africa
12.2.6.5.4.1. Market
Estimation, 2015 – 2019
12.2.6.5.4.2. Market
Forecast, 2020 – 2028
12.2.6.5.5. Latin
America
12.2.6.5.5.1. Market
Estimation, 2015 – 2019
12.2.6.5.5.2. Market
Forecast, 2020 – 2028
12.3. Key
Segment for Channeling Investments
12.3.1. By
Targets
13. Global
Immuno Oncology Assays Market Analysis and Forecasts, 2020 – 2028
13.1. Overview
13.2. Global
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Indication
13.2.1. Lung
Cancer
13.2.1.1. Definition
13.2.1.2. Market
Estimation and Penetration, 2015 – 2019
13.2.1.3. Market
Forecast, 2020 – 2028
13.2.1.4. Compound
Annual Growth Rate (CAGR)
13.2.1.5. Regional
Bifurcation
13.2.1.5.1. North
America
13.2.1.5.1.1. Market
Estimation, 2015 – 2019
13.2.1.5.1.2. Market
Forecast, 2020 – 2028
13.2.1.5.2. Europe
13.2.1.5.2.1. Market
Estimation, 2015 – 2019
13.2.1.5.2.2. Market
Forecast, 2020 – 2028
13.2.1.5.3. Asia
Pacific
13.2.1.5.3.1. Market
Estimation, 2015 – 2019
13.2.1.5.3.2. Market
Forecast, 2020 – 2028
13.2.1.5.4. Middle
East and Africa
13.2.1.5.4.1. Market
Estimation, 2015 – 2019
13.2.1.5.4.2. Market
Forecast, 2020 – 2028
13.2.1.5.5. Latin
America
13.2.1.5.5.1. Market
Estimation, 2015 – 2019
13.2.1.5.5.2. Market
Forecast, 2020 – 2028
13.2.2. Colorectal
Cancer
13.2.2.1. Definition
13.2.2.2. Market
Estimation and Penetration, 2015 – 2019
13.2.2.3. Market
Forecast, 2020 – 2028
13.2.2.4. Compound
Annual Growth Rate (CAGR)
13.2.2.5. Regional
Bifurcation
13.2.2.5.1. North
America
13.2.2.5.1.1. Market
Estimation, 2015 – 2019
13.2.2.5.1.2. Market
Forecast, 2020 – 2028
13.2.2.5.2. Europe
13.2.2.5.2.1. Market
Estimation, 2015 – 2019
13.2.2.5.2.2. Market
Forecast, 2020 – 2028
13.2.2.5.3. Asia
Pacific
13.2.2.5.3.1. Market
Estimation, 2015 – 2019
13.2.2.5.3.2. Market
Forecast, 2020 – 2028
13.2.2.5.4. Middle
East and Africa
13.2.2.5.4.1. Market
Estimation, 2015 – 2019
13.2.2.5.4.2. Market
Forecast, 2020 – 2028
13.2.2.5.5. Latin
America
13.2.2.5.5.1. Market
Estimation, 2015 – 2019
13.2.2.5.5.2. Market
Forecast, 2020 – 2028
13.2.3. Melanoma
13.2.3.1. Definition
13.2.3.2. Market
Estimation and Penetration, 2015 – 2019
13.2.3.3. Market
Forecast, 2020 – 2028
13.2.3.4. Compound
Annual Growth Rate (CAGR)
13.2.3.5. Regional
Bifurcation
13.2.3.5.1. North
America
13.2.3.5.1.1. Market
Estimation, 2015 – 2019
13.2.3.5.1.2. Market
Forecast, 2020 – 2028
13.2.3.5.2. Europe
13.2.3.5.2.1. Market
Estimation, 2015 – 2019
13.2.3.5.2.2. Market
Forecast, 2020 – 2028
13.2.3.5.3. Asia
Pacific
13.2.3.5.3.1. Market
Estimation, 2015 – 2019
13.2.3.5.3.2. Market
Forecast, 2020 – 2028
13.2.3.5.4. Middle
East and Africa
13.2.3.5.4.1. Market
Estimation, 2015 – 2019
13.2.3.5.4.2. Market
Forecast, 2020 – 2028
13.2.3.5.5. Latin
America
13.2.3.5.5.1. Market
Estimation, 2015 – 2019
13.2.3.5.5.2. Market
Forecast, 2020 – 2028
13.2.4. Bladder
Cancer
13.2.4.1. Definition
13.2.4.2. Market
Estimation and Penetration, 2015 – 2019
13.2.4.3. Market
Forecast, 2020 – 2028
13.2.4.4. Compound
Annual Growth Rate (CAGR)
13.2.4.5. Regional
Bifurcation
13.2.4.5.1. North
America
13.2.4.5.1.1. Market
Estimation, 2015 – 2019
13.2.4.5.1.2. Market
Forecast, 2020 – 2028
13.2.4.5.2. Europe
13.2.4.5.2.1. Market
Estimation, 2015 – 2019
13.2.4.5.2.2. Market
Forecast, 2020 – 2028
13.2.4.5.3. Asia
Pacific
13.2.4.5.3.1. Market
Estimation, 2015 – 2019
13.2.4.5.3.2. Market
Forecast, 2020 – 2028
13.2.4.5.4. Middle
East and Africa
13.2.4.5.4.1. Market
Estimation, 2015 – 2019
13.2.4.5.4.2. Market
Forecast, 2020 – 2028
13.2.4.5.5. Latin
America
13.2.4.5.5.1. Market
Estimation, 2015 – 2019
13.2.4.5.5.2. Market
Forecast, 2020 – 2028
13.2.5. Other
Cancers
13.2.5.1. Definition
13.2.5.2. Market
Estimation and Penetration, 2015 – 2019
13.2.5.3. Market
Forecast, 2020 – 2028
13.2.5.4. Compound
Annual Growth Rate (CAGR)
13.2.5.5. Regional
Bifurcation
13.2.5.5.1. North
America
13.2.5.5.1.1. Market
Estimation, 2015 – 2019
13.2.5.5.1.2. Market
Forecast, 2020 – 2028
13.2.5.5.2. Europe
13.2.5.5.2.1. Market
Estimation, 2015 – 2019
13.2.5.5.2.2. Market
Forecast, 2020 – 2028
13.2.5.5.3. Asia
Pacific
13.2.5.5.3.1. Market
Estimation, 2015 – 2019
13.2.5.5.3.2. Market
Forecast, 2020 – 2028
13.2.5.5.4. Middle
East and Africa
13.2.5.5.4.1. Market
Estimation, 2015 – 2019
13.2.5.5.4.2. Market
Forecast, 2020 – 2028
13.2.5.5.5. Latin
America
13.2.5.5.5.1. Market
Estimation, 2015 – 2019
13.2.5.5.5.2. Market
Forecast, 2020 – 2028
13.3. Key
Segment for Channeling Investments
13.3.1. By
Indication
14. Global
Immuno Oncology Assays Market Analysis and Forecasts, 2020 – 2028
14.1. Overview
14.2. Global
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
14.2.1. Research
Solutions (Definition, Market Estimation and Penetration, 2015 – 2019, Market
Estimation (2015 – 2019), Market Forecast (2020 – 2028), Compound Annual Growth
Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle
East and Africa, Latin America) and Information on Tumor Microenvironment and
Immune Composition, Tumor Mutational Burden and Neoantigens, Cancer Microbiome
Research, Immunotherapy Research Publications, Others)
14.2.1.1. Tumor
Microenvironment and Immune Composition
14.2.1.2. Tumor
Mutational Burden and Neoantigens
14.2.1.3. Cancer
Microbiome Research
14.2.1.4. Immunotherapy
Research Publications
14.2.1.5. Others
14.2.2. Others
14.2.2.1. Definition
14.2.2.2. Market
Estimation and Penetration, 2015 – 2019
14.2.2.3. Market
Forecast, 2020 – 2028
14.2.2.4. Compound
Annual Growth Rate (CAGR)
14.2.2.5. Regional
Bifurcation
14.2.2.5.1. North
America
14.2.2.5.1.1. Market
Estimation, 2015 – 2019
14.2.2.5.1.2. Market
Forecast, 2020 – 2028
14.2.2.5.2. Europe
14.2.2.5.2.1. Market
Estimation, 2015 – 2019
14.2.2.5.2.2. Market
Forecast, 2020 – 2028
14.2.2.5.3. Asia
Pacific
14.2.2.5.3.1. Market
Estimation, 2015 – 2019
14.2.2.5.3.2. Market
Forecast, 2020 – 2028
14.2.2.5.4. Middle
East and Africa
14.2.2.5.4.1. Market
Estimation, 2015 – 2019
14.2.2.5.4.2. Market
Forecast, 2020 – 2028
14.2.2.5.5. Latin
America
14.2.2.5.5.1. Market
Estimation, 2015 – 2019
14.2.2.5.5.2. Market
Forecast, 2020 – 2028
14.3. Key
Segment for Channeling Investments
14.3.1. By
Usage
15. North
America Immuno Oncology Assays Market Analysis and Forecasts, 2020 - 2028
15.1. Overview
15.1.1. North
America Immuno Oncology Assays Market Revenue (US$ Mn)
15.2. North
America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Component
15.2.1. Consumables
15.2.1.1. Cytotoxicity
Assays
15.2.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
15.2.1.3. Functional
Assays
15.2.1.4. Custom
15.2.1.5. Others
15.2.2. Software
Platform
15.2.2.1. Immunoassay
15.2.2.2. PCR
15.2.2.3. NGS
15.2.2.4. Flow
Cytometry
15.2.2.5. Others
15.3. North
America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Technology
15.3.1. 2D
15.3.2. 3D
15.4. North
America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell
Types
15.4.1. Natural
Killer Cells
15.4.2. Macrophages
15.4.3. Dendritic
Cells
15.4.4. Neutrophils
15.4.5. Fibroblasts
15.4.6. Others
15.5. North
America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Application
15.5.1. Screen
and Develop Antibodies
15.5.2. Small
Molecules
15.5.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
15.5.4. ADCC
15.5.5. ADCP
15.5.6. T Cell
Redirection
15.5.7. Adoptive
T Cell Therapy
15.5.8. Others
15.6. North
America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Targets
15.6.1. PD-1
15.6.2. SIRP?
15.6.3. CTLA4
15.6.4. OX40
15.6.5. ICOS
15.6.6. Others
15.7. North
America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Indication
15.7.1. Lung
Cancer
15.7.2. Colorectal
Cancer
15.7.3. Melanoma
15.7.4. Bladder
Cancer
15.7.5. Other
Cancers
15.8. North America
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
15.8.1. Research
Solutions
15.8.1.1. Tumor
Microenvironment and Immune Composition
15.8.1.2. Tumor
Mutational Burden and Neoantigens
15.8.1.3. Cancer
Microbiome Research
15.8.1.4. Immunotherapy
Research Publications
15.8.1.5. Others
15.8.2. Others
15.9. North
America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Country
15.9.1. U.S
15.9.1.1. U.S
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Component
15.9.1.1.1. Consumables
15.9.1.1.1.1. Cytotoxicity
Assays
15.9.1.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
15.9.1.1.1.3. Functional
Assays
15.9.1.1.1.4. Custom
15.9.1.1.1.5. Others
15.9.1.1.2. Software
Platform
15.9.1.1.2.1. Immunoassay
15.9.1.1.2.2. PCR
15.9.1.1.2.3. NGS
15.9.1.1.2.4. Flow
Cytometry
15.9.1.1.2.5. Others
15.9.1.2. U.S
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Technology
15.9.1.2.1. 2D
15.9.1.2.2. 3D
15.9.1.3. U.S
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell Types
15.9.1.3.1. Natural
Killer Cells
15.9.1.3.2. Macrophages
15.9.1.3.3. Dendritic
Cells
15.9.1.3.4. Neutrophils
15.9.1.3.5. Fibroblasts
15.9.1.3.6. Others
15.9.1.4. U.S
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Application
15.9.1.4.1. Screen
and Develop Antibodies
15.9.1.4.2. Small
Molecules
15.9.1.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
15.9.1.4.4. ADCC
15.9.1.4.5. ADCP
15.9.1.4.6. T
Cell Redirection
15.9.1.4.7. Adoptive
T Cell Therapy
15.9.1.4.8. Others
15.9.1.5. U.S
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
15.9.1.5.1. PD-1
15.9.1.5.2. SIRP?
15.9.1.5.3. CTLA4
15.9.1.5.4. OX40
15.9.1.5.5. ICOS
15.9.1.5.6. Others
15.9.1.6. U.S
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Indication
15.9.1.6.1. Lung
Cancer
15.9.1.6.2. Colorectal
Cancer
15.9.1.6.3. Melanoma
15.9.1.6.4. Bladder
Cancer
15.9.1.6.5. Other
Cancers
15.9.1.7. U.S
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
15.9.1.7.1. Research
Solutions
15.9.1.7.1.1. Tumor
Microenvironment and Immune Composition
15.9.1.7.1.2. Tumor
Mutational Burden and Neoantigens
15.9.1.7.1.3. Cancer
Microbiome Research
15.9.1.7.1.4. Immunotherapy
Research Publications
15.9.1.7.1.5. Others
15.9.1.7.2. Others
15.9.2. Canada
15.9.2.1. Canada
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Component
15.9.2.1.1. Consumables
15.9.2.1.1.1. Cytotoxicity
Assays
15.9.2.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
15.9.2.1.1.3. Functional
Assays
15.9.2.1.1.4. Custom
15.9.2.1.1.5. Others
15.9.2.1.2. Software
Platform
15.9.2.1.2.1. Immunoassay
15.9.2.1.2.2. PCR
15.9.2.1.2.3. NGS
15.9.2.1.2.4. Flow
Cytometry
15.9.2.1.2.5. Others
15.9.2.2. Canada
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Technology
15.9.2.2.1. 2D
15.9.2.2.2. 3D
15.9.2.3. Canada
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell Types
15.9.2.3.1. Natural
Killer Cells
15.9.2.3.2. Macrophages
15.9.2.3.3. Dendritic
Cells
15.9.2.3.4. Neutrophils
15.9.2.3.5. Fibroblasts
15.9.2.3.6. Others
15.9.2.4. Canada
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Application
15.9.2.4.1. Screen
and Develop Antibodies
15.9.2.4.2. Small
Molecules
15.9.2.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
15.9.2.4.4. ADCC
15.9.2.4.5. ADCP
15.9.2.4.6. T
Cell Redirection
15.9.2.4.7. Adoptive
T Cell Therapy
15.9.2.4.8. Others
15.9.2.5. Canada
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
15.9.2.5.1. PD-1
15.9.2.5.2. SIRP?
15.9.2.5.3. CTLA4
15.9.2.5.4. OX40
15.9.2.5.5. ICOS
15.9.2.5.6. Others
15.9.2.6. Canada
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Indication
15.9.2.6.1. Lung
Cancer
15.9.2.6.2. Colorectal
Cancer
15.9.2.6.3. Melanoma
15.9.2.6.4. Bladder
Cancer
15.9.2.6.5. Other
Cancers
15.9.2.7. Canada
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
15.9.2.7.1. Research
Solutions
15.9.2.7.1.1. Tumor
Microenvironment and Immune Composition
15.9.2.7.1.2. Tumor
Mutational Burden and Neoantigens
15.9.2.7.1.3. Cancer
Microbiome Research
15.9.2.7.1.4. Immunotherapy
Research Publications
15.9.2.7.1.5. Others
15.9.2.7.2. Others
15.9.3. Mexico
15.9.3.1. Mexico
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Component
15.9.3.1.1. Consumables
15.9.3.1.1.1. Cytotoxicity
Assays
15.9.3.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
15.9.3.1.1.3. Functional
Assays
15.9.3.1.1.4. Custom
15.9.3.1.1.5. Others
15.9.3.1.2. Software
Platform
15.9.3.1.2.1. Immunoassay
15.9.3.1.2.2. PCR
15.9.3.1.2.3. NGS
15.9.3.1.2.4. Flow
Cytometry
15.9.3.1.2.5. Others
15.9.3.2. Mexico
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Technology
15.9.3.2.1. 2D
15.9.3.2.2. 3D
15.9.3.3. Mexico
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell Types
15.9.3.3.1. Natural
Killer Cells
15.9.3.3.2. Macrophages
15.9.3.3.3. Dendritic
Cells
15.9.3.3.4. Neutrophils
15.9.3.3.5. Fibroblasts
15.9.3.3.6. Others
15.9.3.4. Mexico
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Application
15.9.3.4.1. Screen
and Develop Antibodies
15.9.3.4.2. Small
Molecules
15.9.3.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
15.9.3.4.4. ADCC
15.9.3.4.5. ADCP
15.9.3.4.6. T
Cell Redirection
15.9.3.4.7. Adoptive
T Cell Therapy
15.9.3.4.8. Others
15.9.3.5. Mexico
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
15.9.3.5.1. PD-1
15.9.3.5.2. SIRP?
15.9.3.5.3. CTLA4
15.9.3.5.4. OX40
15.9.3.5.5. ICOS
15.9.3.5.6. Others
15.9.3.6. Mexico
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Indication
15.9.3.6.1. Lung
Cancer
15.9.3.6.2. Colorectal
Cancer
15.9.3.6.3. Melanoma
15.9.3.6.4. Bladder
Cancer
15.9.3.6.5. Other
Cancers
15.9.3.7. Mexico
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
15.9.3.7.1. Research
Solutions
15.9.3.7.1.1. Tumor
Microenvironment and Immune Composition
15.9.3.7.1.2. Tumor
Mutational Burden and Neoantigens
15.9.3.7.1.3. Cancer
Microbiome Research
15.9.3.7.1.4. Immunotherapy
Research Publications
15.9.3.7.1.5. Others
15.9.3.7.2. Others
15.9.4. Rest of
North America
15.9.4.1. Rest
of North America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Component
15.9.4.1.1. Consumables
15.9.4.1.1.1. Cytotoxicity
Assays
15.9.4.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
15.9.4.1.1.3. Functional
Assays
15.9.4.1.1.4. Custom
15.9.4.1.1.5. Others
15.9.4.1.2. Software
Platform
15.9.4.1.2.1. Immunoassay
15.9.4.1.2.2. PCR
15.9.4.1.2.3. NGS
15.9.4.1.2.4. Flow
Cytometry
15.9.4.1.2.5. Others
15.9.4.2. Rest
of North America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Technology
15.9.4.2.1. 2D
15.9.4.2.2. 3D
15.9.4.3. Rest
of North America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Cell Types
15.9.4.3.1. Natural
Killer Cells
15.9.4.3.2. Macrophages
15.9.4.3.3. Dendritic
Cells
15.9.4.3.4. Neutrophils
15.9.4.3.5. Fibroblasts
15.9.4.3.6. Others
15.9.4.4. Rest
of North America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Application
15.9.4.4.1. Screen
and Develop Antibodies
15.9.4.4.2. Small
Molecules
15.9.4.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
15.9.4.4.4. ADCC
15.9.4.4.5. ADCP
15.9.4.4.6. T
Cell Redirection
15.9.4.4.7. Adoptive
T Cell Therapy
15.9.4.4.8. Others
15.9.4.5. Rest
of North America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Targets
15.9.4.5.1. PD-1
15.9.4.5.2. SIRP?
15.9.4.5.3. CTLA4
15.9.4.5.4. OX40
15.9.4.5.5. ICOS
15.9.4.5.6. Others
15.9.4.6. Rest of
North America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Indication
15.9.4.6.1. Lung
Cancer
15.9.4.6.2. Colorectal
Cancer
15.9.4.6.3. Melanoma
15.9.4.6.4. Bladder
Cancer
15.9.4.6.5. Other
Cancers
15.9.4.7. Rest
of North America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Usage
15.9.4.7.1. Research
Solutions
15.9.4.7.1.1. Tumor
Microenvironment and Immune Composition
15.9.4.7.1.2. Tumor
Mutational Burden and Neoantigens
15.9.4.7.1.3. Cancer
Microbiome Research
15.9.4.7.1.4. Immunotherapy
Research Publications
15.9.4.7.1.5. Others
15.9.4.7.2. Others
15.10. Key
Segment for Channeling Investments
15.10.1. By
Country
15.10.2. By
Component
15.10.3. By
Technology
15.10.4. By
Cell Types
15.10.5. By
Application
15.10.6. By
Targets
15.10.7. By
Indication
15.10.8. By
Usage
16. Europe
Immuno Oncology Assays Market Analysis and Forecasts, 2020 - 2028
16.1. Overview
16.1.1. Europe
Immuno Oncology Assays Market Revenue (US$ Mn)
16.2. Europe
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Component
16.2.1. Consumables
16.2.1.1. Cytotoxicity
Assays
16.2.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
16.2.1.3. Functional
Assays
16.2.1.4. Custom
16.2.1.5. Others
16.2.2. Software
Platform
16.2.2.1. Immunoassay
16.2.2.2. PCR
16.2.2.3. NGS
16.2.2.4. Flow
Cytometry
16.2.2.5. Others
16.3. Europe
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Technology
16.3.1. 2D
16.3.2. 3D
16.4. Europe
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell Types
16.4.1. Natural
Killer Cells
16.4.2. Macrophages
16.4.3. Dendritic
Cells
16.4.4. Neutrophils
16.4.5. Fibroblasts
16.4.6. Others
16.5. Europe
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Application
16.5.1. Screen
and Develop Antibodies
16.5.2. Small
Molecules
16.5.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
16.5.4. ADCC
16.5.5. ADCP
16.5.6. T Cell
Redirection
16.5.7. Adoptive
T Cell Therapy
16.5.8. Others
16.6. Europe
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
16.6.1. PD-1
16.6.2. SIRP?
16.6.3. CTLA4
16.6.4. OX40
16.6.5. ICOS
16.6.6. Others
16.7. Europe
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Indication
16.7.1. Lung
Cancer
16.7.2. Colorectal
Cancer
16.7.3. Melanoma
16.7.4. Bladder
Cancer
16.7.5. Other
Cancers
16.8. Europe
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
16.8.1. Research
Solutions
16.8.1.1. Tumor
Microenvironment and Immune Composition
16.8.1.2. Tumor
Mutational Burden and Neoantigens
16.8.1.3. Cancer
Microbiome Research
16.8.1.4. Immunotherapy
Research Publications
16.8.1.5. Others
16.8.2. Others
16.9. Europe Immuno
Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Country
16.9.1. France
16.9.1.1. France
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Component
16.9.1.1.1. Consumables
16.9.1.1.1.1. Cytotoxicity
Assays
16.9.1.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
16.9.1.1.1.3. Functional
Assays
16.9.1.1.1.4. Custom
16.9.1.1.1.5. Others
16.9.1.1.2. Software
Platform
16.9.1.1.2.1. Immunoassay
16.9.1.1.2.2. PCR
16.9.1.1.2.3. NGS
16.9.1.1.2.4. Flow
Cytometry
16.9.1.1.2.5. Others
16.9.1.2. France
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Technology
16.9.1.2.1. 2D
16.9.1.2.2. 3D
16.9.1.3. France
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell Types
16.9.1.3.1. Natural
Killer Cells
16.9.1.3.2. Macrophages
16.9.1.3.3. Dendritic
Cells
16.9.1.3.4. Neutrophils
16.9.1.3.5. Fibroblasts
16.9.1.3.6. Others
16.9.1.4. France
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Application
16.9.1.4.1. Screen
and Develop Antibodies
16.9.1.4.2. Small
Molecules
16.9.1.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
16.9.1.4.4. ADCC
16.9.1.4.5. ADCP
16.9.1.4.6. T
Cell Redirection
16.9.1.4.7. Adoptive
T Cell Therapy
16.9.1.4.8. Others
16.9.1.5. France
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
16.9.1.5.1. PD-1
16.9.1.5.2. SIRP?
16.9.1.5.3. CTLA4
16.9.1.5.4. OX40
16.9.1.5.5. ICOS
16.9.1.5.6. Others
16.9.1.6. France
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Indication
16.9.1.6.1. Lung
Cancer
16.9.1.6.2. Colorectal
Cancer
16.9.1.6.3. Melanoma
16.9.1.6.4. Bladder
Cancer
16.9.1.6.5. Other
Cancers
16.9.1.7. France
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
16.9.1.7.1. Research
Solutions
16.9.1.7.1.1. Tumor
Microenvironment and Immune Composition
16.9.1.7.1.2. Tumor
Mutational Burden and Neoantigens
16.9.1.7.1.3. Cancer
Microbiome Research
16.9.1.7.1.4. Immunotherapy
Research Publications
16.9.1.7.1.5. Others
16.9.1.7.2. Others
16.9.2. The UK
16.9.2.1. The
UK Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Component
16.9.2.1.1. Consumables
16.9.2.1.1.1. Cytotoxicity
Assays
16.9.2.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
16.9.2.1.1.3. Functional
Assays
16.9.2.1.1.4. Custom
16.9.2.1.1.5. Others
16.9.2.1.2. Software
Platform
16.9.2.1.2.1. Immunoassay
16.9.2.1.2.2. PCR
16.9.2.1.2.3. NGS
16.9.2.1.2.4. Flow
Cytometry
16.9.2.1.2.5. Others
16.9.2.2. The
UK Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Technology
16.9.2.2.1. 2D
16.9.2.2.2. 3D
16.9.2.3. The
UK Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell Types
16.9.2.3.1. Natural
Killer Cells
16.9.2.3.2. Macrophages
16.9.2.3.3. Dendritic
Cells
16.9.2.3.4. Neutrophils
16.9.2.3.5. Fibroblasts
16.9.2.3.6. Others
16.9.2.4. The
UK Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Application
16.9.2.4.1. Screen
and Develop Antibodies
16.9.2.4.2. Small
Molecules
16.9.2.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
16.9.2.4.4. ADCC
16.9.2.4.5. ADCP
16.9.2.4.6. T
Cell Redirection
16.9.2.4.7. Adoptive
T Cell Therapy
16.9.2.4.8. Others
16.9.2.5. The
UK Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
16.9.2.5.1. PD-1
16.9.2.5.2. SIRP?
16.9.2.5.3. CTLA4
16.9.2.5.4. OX40
16.9.2.5.5. ICOS
16.9.2.5.6. Others
16.9.2.6. The
UK Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Indication
16.9.2.6.1. Lung
Cancer
16.9.2.6.2. Colorectal
Cancer
16.9.2.6.3. Melanoma
16.9.2.6.4. Bladder
Cancer
16.9.2.6.5. Other
Cancers
16.9.2.7. The
UK Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
16.9.2.7.1. Research
Solutions
16.9.2.7.1.1. Tumor
Microenvironment and Immune Composition
16.9.2.7.1.2. Tumor
Mutational Burden and Neoantigens
16.9.2.7.1.3. Cancer
Microbiome Research
16.9.2.7.1.4. Immunotherapy
Research Publications
16.9.2.7.1.5. Others
16.9.2.7.2. Others
16.9.3. Spain
16.9.3.1. Spain
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Component
16.9.3.1.1. Consumables
16.9.3.1.1.1. Cytotoxicity
Assays
16.9.3.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
16.9.3.1.1.3. Functional
Assays
16.9.3.1.1.4. Custom
16.9.3.1.1.5. Others
16.9.3.1.2. Software
Platform
16.9.3.1.2.1. Immunoassay
16.9.3.1.2.2. PCR
16.9.3.1.2.3. NGS
16.9.3.1.2.4. Flow
Cytometry
16.9.3.1.2.5. Others
16.9.3.2. Spain
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Technology
16.9.3.2.1. 2D
16.9.3.2.2. 3D
16.9.3.3. Spain
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell Types
16.9.3.3.1. Natural
Killer Cells
16.9.3.3.2. Macrophages
16.9.3.3.3. Dendritic
Cells
16.9.3.3.4. Neutrophils
16.9.3.3.5. Fibroblasts
16.9.3.3.6. Others
16.9.3.4. Spain
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Application
16.9.3.4.1. Screen
and Develop Antibodies
16.9.3.4.2. Small
Molecules
16.9.3.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
16.9.3.4.4. ADCC
16.9.3.4.5. ADCP
16.9.3.4.6. T
Cell Redirection
16.9.3.4.7. Adoptive
T Cell Therapy
16.9.3.4.8. Others
16.9.3.5. Spain
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
16.9.3.5.1. PD-1
16.9.3.5.2. SIRP?
16.9.3.5.3. CTLA4
16.9.3.5.4. OX40
16.9.3.5.5. ICOS
16.9.3.5.6. Others
16.9.3.6. Spain
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Indication
16.9.3.6.1. Lung
Cancer
16.9.3.6.2. Colorectal
Cancer
16.9.3.6.3. Melanoma
16.9.3.6.4. Bladder
Cancer
16.9.3.6.5. Other
Cancers
16.9.3.7. Spain
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
16.9.3.7.1. Research
Solutions
16.9.3.7.1.1. Tumor
Microenvironment and Immune Composition
16.9.3.7.1.2. Tumor
Mutational Burden and Neoantigens
16.9.3.7.1.3. Cancer
Microbiome Research
16.9.3.7.1.4. Immunotherapy
Research Publications
16.9.3.7.1.5. Others
16.9.3.7.2. Others
16.9.4. Germany
16.9.4.1. Germany
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Component
16.9.4.1.1. Consumables
16.9.4.1.1.1. Cytotoxicity
Assays
16.9.4.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
16.9.4.1.1.3. Functional
Assays
16.9.4.1.1.4. Custom
16.9.4.1.1.5. Others
16.9.4.1.2. Software
Platform
16.9.4.1.2.1. Immunoassay
16.9.4.1.2.2. PCR
16.9.4.1.2.3. NGS
16.9.4.1.2.4. Flow
Cytometry
16.9.4.1.2.5. Others
16.9.4.2. Germany
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Technology
16.9.4.2.1. 2D
16.9.4.2.2. 3D
16.9.4.3. Germany
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell Types
16.9.4.3.1. Natural
Killer Cells
16.9.4.3.2. Macrophages
16.9.4.3.3. Dendritic
Cells
16.9.4.3.4. Neutrophils
16.9.4.3.5. Fibroblasts
16.9.4.3.6. Others
16.9.4.4. Germany
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Application
16.9.4.4.1. Screen
and Develop Antibodies
16.9.4.4.2. Small
Molecules
16.9.4.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
16.9.4.4.4. ADCC
16.9.4.4.5. ADCP
16.9.4.4.6. T
Cell Redirection
16.9.4.4.7. Adoptive
T Cell Therapy
16.9.4.4.8. Others
16.9.4.5. Germany
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
16.9.4.5.1. PD-1
16.9.4.5.2. SIRP?
16.9.4.5.3. CTLA4
16.9.4.5.4. OX40
16.9.4.5.5. ICOS
16.9.4.5.6. Others
16.9.4.6. Germany
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Indication
16.9.4.6.1. Lung
Cancer
16.9.4.6.2. Colorectal
Cancer
16.9.4.6.3. Melanoma
16.9.4.6.4. Bladder
Cancer
16.9.4.6.5. Other
Cancers
16.9.4.7. Germany
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
16.9.4.7.1. Research
Solutions
16.9.4.7.1.1. Tumor
Microenvironment and Immune Composition
16.9.4.7.1.2. Tumor
Mutational Burden and Neoantigens
16.9.4.7.1.3. Cancer
Microbiome Research
16.9.4.7.1.4. Immunotherapy
Research Publications
16.9.4.7.1.5. Others
16.9.4.7.2. Others
16.9.5. Italy
16.9.5.1. Italy
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Component
16.9.5.1.1. Consumables
16.9.5.1.1.1. Cytotoxicity
Assays
16.9.5.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
16.9.5.1.1.3. Functional
Assays
16.9.5.1.1.4. Custom
16.9.5.1.1.5. Others
16.9.5.1.2. Software
Platform
16.9.5.1.2.1. Immunoassay
16.9.5.1.2.2. PCR
16.9.5.1.2.3. NGS
16.9.5.1.2.4. Flow
Cytometry
16.9.5.1.2.5. Others
16.9.5.2. Italy
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Technology
16.9.5.2.1. 2D
16.9.5.2.2. 3D
16.9.5.3. Italy
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell Types
16.9.5.3.1. Natural
Killer Cells
16.9.5.3.2. Macrophages
16.9.5.3.3. Dendritic
Cells
16.9.5.3.4. Neutrophils
16.9.5.3.5. Fibroblasts
16.9.5.3.6. Others
16.9.5.4. Italy
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Application
16.9.5.4.1. Screen
and Develop Antibodies
16.9.5.4.2. Small
Molecules
16.9.5.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
16.9.5.4.4. ADCC
16.9.5.4.5. ADCP
16.9.5.4.6. T
Cell Redirection
16.9.5.4.7. Adoptive
T Cell Therapy
16.9.5.4.8. Others
16.9.5.5. Italy
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
16.9.5.5.1. PD-1
16.9.5.5.2. SIRP?
16.9.5.5.3. CTLA4
16.9.5.5.4. OX40
16.9.5.5.5. ICOS
16.9.5.5.6. Others
16.9.5.6. Italy
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Indication
16.9.5.6.1. Lung
Cancer
16.9.5.6.2. Colorectal
Cancer
16.9.5.6.3. Melanoma
16.9.5.6.4. Bladder
Cancer
16.9.5.6.5. Other
Cancers
16.9.5.7. Italy
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
16.9.5.7.1. Research
Solutions
16.9.5.7.1.1. Tumor
Microenvironment and Immune Composition
16.9.5.7.1.2. Tumor
Mutational Burden and Neoantigens
16.9.5.7.1.3. Cancer
Microbiome Research
16.9.5.7.1.4. Immunotherapy
Research Publications
16.9.5.7.1.5. Others
16.9.5.7.2. Others
16.9.6. Nordic
Countries
16.9.6.1. Nordic
Countries Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Component
16.9.6.1.1. Consumables
16.9.6.1.1.1. Cytotoxicity
Assays
16.9.6.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
16.9.6.1.1.3. Functional
Assays
16.9.6.1.1.4. Custom
16.9.6.1.1.5. Others
16.9.6.1.2. Software
Platform
16.9.6.1.2.1. Immunoassay
16.9.6.1.2.2. PCR
16.9.6.1.2.3. NGS
16.9.6.1.2.4. Flow
Cytometry
16.9.6.1.2.5. Others
16.9.6.2. Nordic
Countries Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Technology
16.9.6.2.1. 2D
16.9.6.2.2. 3D
16.9.6.3. Nordic
Countries Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell
Types
16.9.6.3.1. Natural
Killer Cells
16.9.6.3.2. Macrophages
16.9.6.3.3. Dendritic
Cells
16.9.6.3.4. Neutrophils
16.9.6.3.5. Fibroblasts
16.9.6.3.6. Others
16.9.6.4. Nordic
Countries Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Application
16.9.6.4.1. Screen
and Develop Antibodies
16.9.6.4.2. Small
Molecules
16.9.6.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
16.9.6.4.4. ADCC
16.9.6.4.5. ADCP
16.9.6.4.6. T
Cell Redirection
16.9.6.4.7. Adoptive
T Cell Therapy
16.9.6.4.8. Others
16.9.6.5. Nordic
Countries Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Targets
16.9.6.5.1. PD-1
16.9.6.5.2. SIRP?
16.9.6.5.3. CTLA4
16.9.6.5.4. OX40
16.9.6.5.5. ICOS
16.9.6.5.6. Others
16.9.6.6. Nordic
Countries Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Indication
16.9.6.6.1. Lung
Cancer
16.9.6.6.2. Colorectal
Cancer
16.9.6.6.3. Melanoma
16.9.6.6.4. Bladder
Cancer
16.9.6.6.5. Other
Cancers
16.9.6.7. Nordic
Countries Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Usage
16.9.6.7.1. Research
Solutions
16.9.6.7.1.1. Tumor
Microenvironment and Immune Composition
16.9.6.7.1.2. Tumor
Mutational Burden and Neoantigens
16.9.6.7.1.3. Cancer
Microbiome Research
16.9.6.7.1.4. Immunotherapy
Research Publications
16.9.6.7.1.5. Others
16.9.6.7.2. Others
16.9.6.8. Nordic
Countries Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Country
16.9.6.8.1. Denmark
16.9.6.8.2. Finland
16.9.6.8.3. Iceland
16.9.6.8.4. Sweden
16.9.6.8.5. Norway
16.9.7. Benelux
Union
16.9.7.1. Benelux
Union Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Component
16.9.7.1.1. Consumables
16.9.7.1.1.1. Cytotoxicity
Assays
16.9.7.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
16.9.7.1.1.3. Functional
Assays
16.9.7.1.1.4. Custom
16.9.7.1.1.5. Others
16.9.7.1.2. Software
Platform
16.9.7.1.2.1. Immunoassay
16.9.7.1.2.2. PCR
16.9.7.1.2.3. NGS
16.9.7.1.2.4. Flow
Cytometry
16.9.7.1.2.5. Others
16.9.7.2. Benelux
Union Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Technology
16.9.7.2.1. 2D
16.9.7.2.2. 3D
16.9.7.3. Benelux
Union Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell
Types
16.9.7.3.1. Natural
Killer Cells
16.9.7.3.2. Macrophages
16.9.7.3.3. Dendritic
Cells
16.9.7.3.4. Neutrophils
16.9.7.3.5. Fibroblasts
16.9.7.3.6. Others
16.9.7.4. Benelux
Union Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Application
16.9.7.4.1. Screen
and Develop Antibodies
16.9.7.4.2. Small
Molecules
16.9.7.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
16.9.7.4.4. ADCC
16.9.7.4.5. ADCP
16.9.7.4.6. T
Cell Redirection
16.9.7.4.7. Adoptive
T Cell Therapy
16.9.7.4.8. Others
16.9.7.5. Benelux
Union Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
16.9.7.5.1. PD-1
16.9.7.5.2. SIRP?
16.9.7.5.3. CTLA4
16.9.7.5.4. OX40
16.9.7.5.5. ICOS
16.9.7.5.6. Others
16.9.7.6. Benelux
Union Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Indication
16.9.7.6.1. Lung
Cancer
16.9.7.6.2. Colorectal
Cancer
16.9.7.6.3. Melanoma
16.9.7.6.4. Bladder
Cancer
16.9.7.6.5. Other
Cancers
16.9.7.7. Benelux
Union Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
16.9.7.7.1. Research
Solutions
16.9.7.7.1.1. Tumor
Microenvironment and Immune Composition
16.9.7.7.1.2. Tumor
Mutational Burden and Neoantigens
16.9.7.7.1.3. Cancer
Microbiome Research
16.9.7.7.1.4. Immunotherapy
Research Publications
16.9.7.7.1.5. Others
16.9.7.7.2. Others
16.9.7.8. Benelux
Union Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Country
16.9.7.8.1. Belgium
16.9.7.8.2. The
Netherlands
16.9.7.8.3. Luxembourg
16.9.8. Rest of
Europe
16.9.8.1. Rest
of Europe Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Component
16.9.8.1.1. Consumables
16.9.8.1.1.1. Cytotoxicity
Assays
16.9.8.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
16.9.8.1.1.3. Functional
Assays
16.9.8.1.1.4. Custom
16.9.8.1.1.5. Others
16.9.8.1.2. Software
Platform
16.9.8.1.2.1. Immunoassay
16.9.8.1.2.2. PCR
16.9.8.1.2.3. NGS
16.9.8.1.2.4. Flow
Cytometry
16.9.8.1.2.5. Others
16.9.8.2. Rest
of Europe Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Technology
16.9.8.2.1. 2D
16.9.8.2.2. 3D
16.9.8.3. Rest
of Europe Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell
Types
16.9.8.3.1. Natural
Killer Cells
16.9.8.3.2. Macrophages
16.9.8.3.3. Dendritic
Cells
16.9.8.3.4. Neutrophils
16.9.8.3.5. Fibroblasts
16.9.8.3.6. Others
16.9.8.4. Rest
of Europe Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Application
16.9.8.4.1. Screen
and Develop Antibodies
16.9.8.4.2. Small
Molecules
16.9.8.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
16.9.8.4.4. ADCC
16.9.8.4.5. ADCP
16.9.8.4.6. T
Cell Redirection
16.9.8.4.7. Adoptive
T Cell Therapy
16.9.8.4.8. Others
16.9.8.5. Rest
of Europe Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Targets
16.9.8.5.1. PD-1
16.9.8.5.2. SIRP?
16.9.8.5.3. CTLA4
16.9.8.5.4. OX40
16.9.8.5.5. ICOS
16.9.8.5.6. Others
16.9.8.6. Rest
of Europe Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Indication
16.9.8.6.1. Lung
Cancer
16.9.8.6.2. Colorectal
Cancer
16.9.8.6.3. Melanoma
16.9.8.6.4. Bladder
Cancer
16.9.8.6.5. Other
Cancers
16.9.8.7. Rest
of Europe Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Usage
16.9.8.7.1. Research
Solutions
16.9.8.7.1.1. Tumor
Microenvironment and Immune Composition
16.9.8.7.1.2. Tumor
Mutational Burden and Neoantigens
16.9.8.7.1.3. Cancer
Microbiome Research
16.9.8.7.1.4. Immunotherapy
Research Publications
16.9.8.7.1.5. Others
16.9.8.7.2. Others
16.10. Key
Segment for Channeling Investments
16.10.1. By
Country
16.10.2. By
Component
16.10.3. By
Technology
16.10.4. By
Cell Types
16.10.5. By
Application
16.10.6. By
Targets
16.10.7. By
Indication
16.10.8. By
Usage
17. Asia
Pacific Immuno Oncology Assays Market Analysis and Forecasts, 2020 - 2028
17.1. Overview
17.1.1. Asia
Pacific Immuno Oncology Assays Market Revenue (US$ Mn)
17.2. Asia
Pacific Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Component
17.2.1. Consumables
17.2.1.1. Cytotoxicity
Assays
17.2.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
17.2.1.3. Functional
Assays
17.2.1.4. Custom
17.2.1.5. Others
17.2.2. Software
Platform
17.2.2.1. Immunoassay
17.2.2.2. PCR
17.2.2.3. NGS
17.2.2.4. Flow
Cytometry
17.2.2.5. Others
17.3. Asia
Pacific Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Technology
17.3.1. 2D
17.3.2. 3D
17.4. Asia
Pacific Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell
Types
17.4.1. Natural
Killer Cells
17.4.2. Macrophages
17.4.3. Dendritic
Cells
17.4.4. Neutrophils
17.4.5. Fibroblasts
17.4.6. Others
17.5. Asia
Pacific Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Application
17.5.1. Screen
and Develop Antibodies
17.5.2. Small
Molecules
17.5.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
17.5.4. ADCC
17.5.5. ADCP
17.5.6. T Cell
Redirection
17.5.7. Adoptive
T Cell Therapy
17.5.8. Others
17.6. Asia
Pacific Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Targets
17.6.1. PD-1
17.6.2. SIRP?
17.6.3. CTLA4
17.6.4. OX40
17.6.5. ICOS
17.6.6. Others
17.7. Asia
Pacific Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Indication
17.7.1. Lung
Cancer
17.7.2. Colorectal
Cancer
17.7.3. Melanoma
17.7.4. Bladder
Cancer
17.7.5. Other
Cancers
17.8. Asia
Pacific Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
17.8.1. Research
Solutions
17.8.1.1. Tumor
Microenvironment and Immune Composition
17.8.1.2. Tumor
Mutational Burden and Neoantigens
17.8.1.3. Cancer
Microbiome Research
17.8.1.4. Immunotherapy
Research Publications
17.8.1.5. Others
17.8.2. Others
17.9. Asia
Pacific Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Country
17.9.1. China
17.9.1.1. China
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Component
17.9.1.1.1. Consumables
17.9.1.1.1.1. Cytotoxicity
Assays
17.9.1.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
17.9.1.1.1.3. Functional
Assays
17.9.1.1.1.4. Custom
17.9.1.1.1.5. Others
17.9.1.1.2. Software
Platform
17.9.1.1.2.1. Immunoassay
17.9.1.1.2.2. PCR
17.9.1.1.2.3. NGS
17.9.1.1.2.4. Flow
Cytometry
17.9.1.1.2.5. Others
17.9.1.2. China
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Technology
17.9.1.2.1. 2D
17.9.1.2.2. 3D
17.9.1.3. China
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell Types
17.9.1.3.1. Natural
Killer Cells
17.9.1.3.2. Macrophages
17.9.1.3.3. Dendritic
Cells
17.9.1.3.4. Neutrophils
17.9.1.3.5. Fibroblasts
17.9.1.3.6. Others
17.9.1.4. China
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Application
17.9.1.4.1. Screen
and Develop Antibodies
17.9.1.4.2. Small
Molecules
17.9.1.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
17.9.1.4.4. ADCC
17.9.1.4.5. ADCP
17.9.1.4.6. T
Cell Redirection
17.9.1.4.7. Adoptive
T Cell Therapy
17.9.1.4.8. Others
17.9.1.5. China
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
17.9.1.5.1. PD-1
17.9.1.5.2. SIRP?
17.9.1.5.3. CTLA4
17.9.1.5.4. OX40
17.9.1.5.5. ICOS
17.9.1.5.6. Others
17.9.1.6. China
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Indication
17.9.1.6.1. Lung
Cancer
17.9.1.6.2. Colorectal
Cancer
17.9.1.6.3. Melanoma
17.9.1.6.4. Bladder
Cancer
17.9.1.6.5. Other
Cancers
17.9.1.7. China
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
17.9.1.7.1. Research
Solutions
17.9.1.7.1.1. Tumor
Microenvironment and Immune Composition
17.9.1.7.1.2. Tumor
Mutational Burden and Neoantigens
17.9.1.7.1.3. Cancer
Microbiome Research
17.9.1.7.1.4. Immunotherapy
Research Publications
17.9.1.7.1.5. Others
17.9.1.7.2. Others
17.9.2. Japan
17.9.2.1. Japan
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Component
17.9.2.1.1. Consumables
17.9.2.1.1.1. Cytotoxicity
Assays
17.9.2.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
17.9.2.1.1.3. Functional
Assays
17.9.2.1.1.4. Custom
17.9.2.1.1.5. Others
17.9.2.1.2. Software
Platform
17.9.2.1.2.1. Immunoassay
17.9.2.1.2.2. PCR
17.9.2.1.2.3. NGS
17.9.2.1.2.4. Flow
Cytometry
17.9.2.1.2.5. Others
17.9.2.2. Japan
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Technology
17.9.2.2.1. 2D
17.9.2.2.2. 3D
17.9.2.3. Japan
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell Types
17.9.2.3.1. Natural
Killer Cells
17.9.2.3.2. Macrophages
17.9.2.3.3. Dendritic
Cells
17.9.2.3.4. Neutrophils
17.9.2.3.5. Fibroblasts
17.9.2.3.6. Others
17.9.2.4. Japan
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Application
17.9.2.4.1. Screen
and Develop Antibodies
17.9.2.4.2. Small
Molecules
17.9.2.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
17.9.2.4.4. ADCC
17.9.2.4.5. ADCP
17.9.2.4.6. T
Cell Redirection
17.9.2.4.7. Adoptive
T Cell Therapy
17.9.2.4.8. Others
17.9.2.5. Japan
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
17.9.2.5.1. PD-1
17.9.2.5.2. SIRP?
17.9.2.5.3. CTLA4
17.9.2.5.4. OX40
17.9.2.5.5. ICOS
17.9.2.5.6. Others
17.9.2.6. Japan
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Indication
17.9.2.6.1. Lung
Cancer
17.9.2.6.2. Colorectal
Cancer
17.9.2.6.3. Melanoma
17.9.2.6.4. Bladder
Cancer
17.9.2.6.5. Other
Cancers
17.9.2.7. Japan
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
17.9.2.7.1. Research
Solutions
17.9.2.7.1.1. Tumor
Microenvironment and Immune Composition
17.9.2.7.1.2. Tumor
Mutational Burden and Neoantigens
17.9.2.7.1.3. Cancer
Microbiome Research
17.9.2.7.1.4. Immunotherapy
Research Publications
17.9.2.7.1.5. Others
17.9.2.7.2. Others
17.9.3. India
17.9.3.1. India
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Component
17.9.3.1.1. Consumables
17.9.3.1.1.1. Cytotoxicity
Assays
17.9.3.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
17.9.3.1.1.3. Functional
Assays
17.9.3.1.1.4. Custom
17.9.3.1.1.5. Others
17.9.3.1.2. Software
Platform
17.9.3.1.2.1. Immunoassay
17.9.3.1.2.2. PCR
17.9.3.1.2.3. NGS
17.9.3.1.2.4. Flow
Cytometry
17.9.3.1.2.5. Others
17.9.3.2. India
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Technology
17.9.3.2.1. 2D
17.9.3.2.2. 3D
17.9.3.3. India
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell Types
17.9.3.3.1. Natural
Killer Cells
17.9.3.3.2. Macrophages
17.9.3.3.3. Dendritic
Cells
17.9.3.3.4. Neutrophils
17.9.3.3.5. Fibroblasts
17.9.3.3.6. Others
17.9.3.4. India
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Application
17.9.3.4.1. Screen
and Develop Antibodies
17.9.3.4.2. Small
Molecules
17.9.3.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
17.9.3.4.4. ADCC
17.9.3.4.5. ADCP
17.9.3.4.6. T
Cell Redirection
17.9.3.4.7. Adoptive
T Cell Therapy
17.9.3.4.8. Others
17.9.3.5. India
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
17.9.3.5.1. PD-1
17.9.3.5.2. SIRP?
17.9.3.5.3. CTLA4
17.9.3.5.4. OX40
17.9.3.5.5. ICOS
17.9.3.5.6. Others
17.9.3.6. India
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Indication
17.9.3.6.1. Lung
Cancer
17.9.3.6.2. Colorectal
Cancer
17.9.3.6.3. Melanoma
17.9.3.6.4. Bladder
Cancer
17.9.3.6.5. Other
Cancers
17.9.3.7. India
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
17.9.3.7.1. Research
Solutions
17.9.3.7.1.1. Tumor
Microenvironment and Immune Composition
17.9.3.7.1.2. Tumor
Mutational Burden and Neoantigens
17.9.3.7.1.3. Cancer
Microbiome Research
17.9.3.7.1.4. Immunotherapy
Research Publications
17.9.3.7.1.5. Others
17.9.3.7.2. Others
17.9.4. New
Zealand
17.9.4.1. New
Zealand Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Component
17.9.4.1.1. Consumables
17.9.4.1.1.1. Cytotoxicity
Assays
17.9.4.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
17.9.4.1.1.3. Functional
Assays
17.9.4.1.1.4. Custom
17.9.4.1.1.5. Others
17.9.4.1.2. Software
Platform
17.9.4.1.2.1. Immunoassay
17.9.4.1.2.2. PCR
17.9.4.1.2.3. NGS
17.9.4.1.2.4. Flow
Cytometry
17.9.4.1.2.5. Others
17.9.4.2. New
Zealand Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Technology
17.9.4.2.1. 2D
17.9.4.2.2. 3D
17.9.4.3. New
Zealand Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell
Types
17.9.4.3.1. Natural
Killer Cells
17.9.4.3.2. Macrophages
17.9.4.3.3. Dendritic
Cells
17.9.4.3.4. Neutrophils
17.9.4.3.5. Fibroblasts
17.9.4.3.6. Others
17.9.4.4. New
Zealand Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Application
17.9.4.4.1. Screen
and Develop Antibodies
17.9.4.4.2. Small
Molecules
17.9.4.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
17.9.4.4.4. ADCC
17.9.4.4.5. ADCP
17.9.4.4.6. T
Cell Redirection
17.9.4.4.7. Adoptive
T Cell Therapy
17.9.4.4.8. Others
17.9.4.5. New
Zealand Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Targets
17.9.4.5.1. PD-1
17.9.4.5.2. SIRP?
17.9.4.5.3. CTLA4
17.9.4.5.4. OX40
17.9.4.5.5. ICOS
17.9.4.5.6. Others
17.9.4.6. New
Zealand Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Indication
17.9.4.6.1. Lung
Cancer
17.9.4.6.2. Colorectal
Cancer
17.9.4.6.3. Melanoma
17.9.4.6.4. Bladder
Cancer
17.9.4.6.5. Other
Cancers
17.9.4.7. New
Zealand Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
17.9.4.7.1. Research
Solutions
17.9.4.7.1.1. Tumor
Microenvironment and Immune Composition
17.9.4.7.1.2. Tumor
Mutational Burden and Neoantigens
17.9.4.7.1.3. Cancer
Microbiome Research
17.9.4.7.1.4. Immunotherapy
Research Publications
17.9.4.7.1.5. Others
17.9.4.7.2. Others
17.9.5. Australia
17.9.5.1. Australia
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Component
17.9.5.1.1. Consumables
17.9.5.1.1.1. Cytotoxicity
Assays
17.9.5.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
17.9.5.1.1.3. Functional
Assays
17.9.5.1.1.4. Custom
17.9.5.1.1.5. Others
17.9.5.1.2. Software
Platform
17.9.5.1.2.1. Immunoassay
17.9.5.1.2.2. PCR
17.9.5.1.2.3. NGS
17.9.5.1.2.4. Flow
Cytometry
17.9.5.1.2.5. Others
17.9.5.2. Australia
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Technology
17.9.5.2.1. 2D
17.9.5.2.2. 3D
17.9.5.3. Australia
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell Types
17.9.5.3.1. Natural
Killer Cells
17.9.5.3.2. Macrophages
17.9.5.3.3. Dendritic
Cells
17.9.5.3.4. Neutrophils
17.9.5.3.5. Fibroblasts
17.9.5.3.6. Others
17.9.5.4. Australia
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Application
17.9.5.4.1. Screen
and Develop Antibodies
17.9.5.4.2. Small
Molecules
17.9.5.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
17.9.5.4.4. ADCC
17.9.5.4.5. ADCP
17.9.5.4.6. T
Cell Redirection
17.9.5.4.7. Adoptive
T Cell Therapy
17.9.5.4.8. Others
17.9.5.5. Australia
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
17.9.5.5.1. PD-1
17.9.5.5.2. SIRP?
17.9.5.5.3. CTLA4
17.9.5.5.4. OX40
17.9.5.5.5. ICOS
17.9.5.5.6. Others
17.9.5.6. Australia
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Indication
17.9.5.6.1. Lung
Cancer
17.9.5.6.2. Colorectal
Cancer
17.9.5.6.3. Melanoma
17.9.5.6.4. Bladder
Cancer
17.9.5.6.5. Other
Cancers
17.9.5.7. Australia
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
17.9.5.7.1. Research
Solutions
17.9.5.7.1.1. Tumor
Microenvironment and Immune Composition
17.9.5.7.1.2. Tumor
Mutational Burden and Neoantigens
17.9.5.7.1.3. Cancer
Microbiome Research
17.9.5.7.1.4. Immunotherapy
Research Publications
17.9.5.7.1.5. Others
17.9.5.7.2. Others
17.9.6. South
Korea
17.9.6.1. South
Korea Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Component
17.9.6.1.1. Consumables
17.9.6.1.1.1. Cytotoxicity
Assays
17.9.6.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
17.9.6.1.1.3. Functional
Assays
17.9.6.1.1.4. Custom
17.9.6.1.1.5. Others
17.9.6.1.2. Software
Platform
17.9.6.1.2.1. Immunoassay
17.9.6.1.2.2. PCR
17.9.6.1.2.3. NGS
17.9.6.1.2.4. Flow
Cytometry
17.9.6.1.2.5. Others
17.9.6.2. South
Korea Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Technology
17.9.6.2.1. 2D
17.9.6.2.2. 3D
17.9.6.3. South
Korea Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell
Types
17.9.6.3.1. Natural
Killer Cells
17.9.6.3.2. Macrophages
17.9.6.3.3. Dendritic
Cells
17.9.6.3.4. Neutrophils
17.9.6.3.5. Fibroblasts
17.9.6.3.6. Others
17.9.6.4. South
Korea Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Application
17.9.6.4.1. Screen
and Develop Antibodies
17.9.6.4.2. Small
Molecules
17.9.6.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
17.9.6.4.4. ADCC
17.9.6.4.5. ADCP
17.9.6.4.6. T
Cell Redirection
17.9.6.4.7. Adoptive
T Cell Therapy
17.9.6.4.8. Others
17.9.6.5. South
Korea Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
17.9.6.5.1. PD-1
17.9.6.5.2. SIRP?
17.9.6.5.3. CTLA4
17.9.6.5.4. OX40
17.9.6.5.5. ICOS
17.9.6.5.6. Others
17.9.6.6. South
Korea Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Indication
17.9.6.6.1. Lung
Cancer
17.9.6.6.2. Colorectal
Cancer
17.9.6.6.3. Melanoma
17.9.6.6.4. Bladder
Cancer
17.9.6.6.5. Other
Cancers
17.9.6.7. South
Korea Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
17.9.6.7.1. Research
Solutions
17.9.6.7.1.1. Tumor
Microenvironment and Immune Composition
17.9.6.7.1.2. Tumor
Mutational Burden and Neoantigens
17.9.6.7.1.3. Cancer
Microbiome Research
17.9.6.7.1.4. Immunotherapy
Research Publications
17.9.6.7.1.5. Others
17.9.6.7.2. Others
17.9.7. Southeast
Asia
17.9.7.1. Southeast
Asia Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Component
17.9.7.1.1. Consumables
17.9.7.1.1.1. Cytotoxicity
Assays
17.9.7.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
17.9.7.1.1.3. Functional
Assays
17.9.7.1.1.4. Custom
17.9.7.1.1.5. Others
17.9.7.1.2. Software
Platform
17.9.7.1.2.1. Immunoassay
17.9.7.1.2.2. PCR
17.9.7.1.2.3. NGS
17.9.7.1.2.4. Flow
Cytometry
17.9.7.1.2.5. Others
17.9.7.2. Southeast
Asia Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Technology
17.9.7.2.1. 2D
17.9.7.2.2. 3D
17.9.7.3. Southeast
Asia Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell
Types
17.9.7.3.1. Natural
Killer Cells
17.9.7.3.2. Macrophages
17.9.7.3.3. Dendritic
Cells
17.9.7.3.4. Neutrophils
17.9.7.3.5. Fibroblasts
17.9.7.3.6. Others
17.9.7.4. Southeast
Asia Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Application
17.9.7.4.1. Screen
and Develop Antibodies
17.9.7.4.2. Small
Molecules
17.9.7.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
17.9.7.4.4. ADCC
17.9.7.4.5. ADCP
17.9.7.4.6. T
Cell Redirection
17.9.7.4.7. Adoptive
T Cell Therapy
17.9.7.4.8. Others
17.9.7.5. Southeast
Asia Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
17.9.7.5.1. PD-1
17.9.7.5.2. SIRP?
17.9.7.5.3. CTLA4
17.9.7.5.4. OX40
17.9.7.5.5. ICOS
17.9.7.5.6. Others
17.9.7.6. Southeast
Asia Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Indication
17.9.7.6.1. Lung
Cancer
17.9.7.6.2. Colorectal
Cancer
17.9.7.6.3. Melanoma
17.9.7.6.4. Bladder
Cancer
17.9.7.6.5. Other
Cancers
17.9.7.7. Southeast
Asia Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
17.9.7.7.1. Research
Solutions
17.9.7.7.1.1. Tumor
Microenvironment and Immune Composition
17.9.7.7.1.2. Tumor
Mutational Burden and Neoantigens
17.9.7.7.1.3. Cancer
Microbiome Research
17.9.7.7.1.4. Immunotherapy
Research Publications
17.9.7.7.1.5. Others
17.9.7.7.2. Others
17.9.7.8. Southeast
Asia Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Country
17.9.7.8.1. Indonesia
17.9.7.8.2. Thailand
17.9.7.8.3. Malaysia
17.9.7.8.4. Singapore
17.9.7.8.5. Rest
of Southeast Asia
17.9.8. Rest of
Asia Pacific
17.9.8.1. Rest
of Asia Pacific Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Component
17.9.8.1.1. Consumables
17.9.8.1.1.1. Cytotoxicity
Assays
17.9.8.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
17.9.8.1.1.3. Functional
Assays
17.9.8.1.1.4. Custom
17.9.8.1.1.5. Others
17.9.8.1.2. Software
Platform
17.9.8.1.2.1. Immunoassay
17.9.8.1.2.2. PCR
17.9.8.1.2.3. NGS
17.9.8.1.2.4. Flow
Cytometry
17.9.8.1.2.5. Others
17.9.8.2. Rest
of Asia Pacific Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Technology
17.9.8.2.1. 2D
17.9.8.2.2. 3D
17.9.8.3. Rest
of Asia Pacific Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Cell Types
17.9.8.3.1. Natural
Killer Cells
17.9.8.3.2. Macrophages
17.9.8.3.3. Dendritic
Cells
17.9.8.3.4. Neutrophils
17.9.8.3.5. Fibroblasts
17.9.8.3.6. Others
17.9.8.4. Rest
of Asia Pacific Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Application
17.9.8.4.1. Screen
and Develop Antibodies
17.9.8.4.2. Small
Molecules
17.9.8.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
17.9.8.4.4. ADCC
17.9.8.4.5. ADCP
17.9.8.4.6. T
Cell Redirection
17.9.8.4.7. Adoptive
T Cell Therapy
17.9.8.4.8. Others
17.9.8.5. Rest
of Asia Pacific Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Targets
17.9.8.5.1. PD-1
17.9.8.5.2. SIRP?
17.9.8.5.3. CTLA4
17.9.8.5.4. OX40
17.9.8.5.5. ICOS
17.9.8.5.6. Others
17.9.8.6. Rest
of Asia Pacific Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Indication
17.9.8.6.1. Lung
Cancer
17.9.8.6.2. Colorectal
Cancer
17.9.8.6.3. Melanoma
17.9.8.6.4. Bladder
Cancer
17.9.8.6.5. Other
Cancers
17.9.8.7. Rest
of Asia Pacific Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Usage
17.9.8.7.1. Research
Solutions
17.9.8.7.1.1. Tumor
Microenvironment and Immune Composition
17.9.8.7.1.2. Tumor
Mutational Burden and Neoantigens
17.9.8.7.1.3. Cancer
Microbiome Research
17.9.8.7.1.4. Immunotherapy
Research Publications
17.9.8.7.1.5. Others
17.9.8.7.2. Others
17.10. Key
Segment for Channeling Investments
17.10.1. By
Country
17.10.2. By
Component
17.10.3. By
Technology
17.10.4. By
Cell Types
17.10.5. By
Application
17.10.6. By
Targets
17.10.7. By
Indication
17.10.8. By
Usage
18. Middle
East and Africa Immuno Oncology Assays Market Analysis and Forecasts, 2020 -
2028
18.1. Overview
18.1.1. Middle
East and Africa Immuno Oncology Assays Market Revenue (US$ Mn)
18.2. Middle
East and Africa Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Component
18.2.1. Consumables
18.2.1.1. Cytotoxicity
Assays
18.2.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
18.2.1.3. Functional
Assays
18.2.1.4. Custom
18.2.1.5. Others
18.2.2. Software
Platform
18.2.2.1. Immunoassay
18.2.2.2. PCR
18.2.2.3. NGS
18.2.2.4. Flow
Cytometry
18.2.2.5. Others
18.3. Middle
East and Africa Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Technology
18.3.1. 2D
18.3.2. 3D
18.4. Middle
East and Africa Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Cell Types
18.4.1. Natural
Killer Cells
18.4.2. Macrophages
18.4.3. Dendritic
Cells
18.4.4. Neutrophils
18.4.5. Fibroblasts
18.4.6. Others
18.5. Middle
East and Africa Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Application
18.5.1. Screen
and Develop Antibodies
18.5.2. Small
Molecules
18.5.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
18.5.4. ADCC
18.5.5. ADCP
18.5.6. T Cell
Redirection
18.5.7. Adoptive
T Cell Therapy
18.5.8. Others
18.6. Middle
East and Africa Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Targets
18.6.1. PD-1
18.6.2. SIRP?
18.6.3. CTLA4
18.6.4. OX40
18.6.5. ICOS
18.6.6. Others
18.7. Middle
East and Africa Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Indication
18.7.1. Lung
Cancer
18.7.2. Colorectal
Cancer
18.7.3. Melanoma
18.7.4. Bladder
Cancer
18.7.5. Other
Cancers
18.8. Middle
East and Africa Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Usage
18.8.1. Research
Solutions
18.8.1.1. Tumor
Microenvironment and Immune Composition
18.8.1.2. Tumor
Mutational Burden and Neoantigens
18.8.1.3. Cancer
Microbiome Research
18.8.1.4. Immunotherapy
Research Publications
18.8.1.5. Others
18.8.2. Others
18.9. Middle
East and Africa Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Country
18.9.1. Saudi
Arabia
18.9.1.1. Saudi
Arabia Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Component
18.9.1.1.1. Consumables
18.9.1.1.1.1. Cytotoxicity
Assays
18.9.1.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
18.9.1.1.1.3. Functional
Assays
18.9.1.1.1.4. Custom
18.9.1.1.1.5. Others
18.9.1.1.2. Software
Platform
18.9.1.1.2.1. Immunoassay
18.9.1.1.2.2. PCR
18.9.1.1.2.3. NGS
18.9.1.1.2.4. Flow
Cytometry
18.9.1.1.2.5. Others
18.9.1.2. Saudi
Arabia Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Technology
18.9.1.2.1. 2D
18.9.1.2.2. 3D
18.9.1.3. Saudi
Arabia Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell
Types
18.9.1.3.1. Natural
Killer Cells
18.9.1.3.2. Macrophages
18.9.1.3.3. Dendritic
Cells
18.9.1.3.4. Neutrophils
18.9.1.3.5. Fibroblasts
18.9.1.3.6. Others
18.9.1.4. Saudi
Arabia Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Application
18.9.1.4.1. Screen
and Develop Antibodies
18.9.1.4.2. Small
Molecules
18.9.1.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
18.9.1.4.4. ADCC
18.9.1.4.5. ADCP
18.9.1.4.6. T
Cell Redirection
18.9.1.4.7. Adoptive
T Cell Therapy
18.9.1.4.8. Others
18.9.1.5. Saudi
Arabia Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
18.9.1.5.1. PD-1
18.9.1.5.2. SIRP?
18.9.1.5.3. CTLA4
18.9.1.5.4. OX40
18.9.1.5.5. ICOS
18.9.1.5.6. Others
18.9.1.6. Saudi
Arabia Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Indication
18.9.1.6.1. Lung
Cancer
18.9.1.6.2. Colorectal
Cancer
18.9.1.6.3. Melanoma
18.9.1.6.4. Bladder
Cancer
18.9.1.6.5. Other
Cancers
18.9.1.7. Saudi
Arabia Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
18.9.1.7.1. Research
Solutions
18.9.1.7.1.1. Tumor
Microenvironment and Immune Composition
18.9.1.7.1.2. Tumor
Mutational Burden and Neoantigens
18.9.1.7.1.3. Cancer
Microbiome Research
18.9.1.7.1.4. Immunotherapy
Research Publications
18.9.1.7.1.5. Others
18.9.1.7.2. Others
18.9.2. UAE
18.9.2.1. UAE
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Component
18.9.2.1.1. Consumables
18.9.2.1.1.1. Cytotoxicity
Assays
18.9.2.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
18.9.2.1.1.3. Functional
Assays
18.9.2.1.1.4. Custom
18.9.2.1.1.5. Others
18.9.2.1.2. Software
Platform
18.9.2.1.2.1. Immunoassay
18.9.2.1.2.2. PCR
18.9.2.1.2.3. NGS
18.9.2.1.2.4. Flow
Cytometry
18.9.2.1.2.5. Others
18.9.2.2. UAE
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Technology
18.9.2.2.1. 2D
18.9.2.2.2. 3D
18.9.2.3. UAE
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell Types
18.9.2.3.1. Natural
Killer Cells
18.9.2.3.2. Macrophages
18.9.2.3.3. Dendritic
Cells
18.9.2.3.4. Neutrophils
18.9.2.3.5. Fibroblasts
18.9.2.3.6. Others
18.9.2.4. UAE
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Application
18.9.2.4.1. Screen
and Develop Antibodies
18.9.2.4.2. Small
Molecules
18.9.2.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
18.9.2.4.4. ADCC
18.9.2.4.5. ADCP
18.9.2.4.6. T
Cell Redirection
18.9.2.4.7. Adoptive
T Cell Therapy
18.9.2.4.8. Others
18.9.2.5. UAE
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
18.9.2.5.1. PD-1
18.9.2.5.2. SIRP?
18.9.2.5.3. CTLA4
18.9.2.5.4. OX40
18.9.2.5.5. ICOS
18.9.2.5.6. Others
18.9.2.6. UAE
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Indication
18.9.2.6.1. Lung
Cancer
18.9.2.6.2. Colorectal
Cancer
18.9.2.6.3. Melanoma
18.9.2.6.4. Bladder
Cancer
18.9.2.6.5. Other
Cancers
18.9.2.7. UAE
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
18.9.2.7.1. Research
Solutions
18.9.2.7.1.1. Tumor
Microenvironment and Immune Composition
18.9.2.7.1.2. Tumor
Mutational Burden and Neoantigens
18.9.2.7.1.3. Cancer
Microbiome Research
18.9.2.7.1.4. Immunotherapy
Research Publications
18.9.2.7.1.5. Others
18.9.2.7.2. Others
18.9.3. Egypt
18.9.3.1. Egypt
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Component
18.9.3.1.1. Consumables
18.9.3.1.1.1. Cytotoxicity
Assays
18.9.3.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
18.9.3.1.1.3. Functional
Assays
18.9.3.1.1.4. Custom
18.9.3.1.1.5. Others
18.9.3.1.2. Software
Platform
18.9.3.1.2.1. Immunoassay
18.9.3.1.2.2. PCR
18.9.3.1.2.3. NGS
18.9.3.1.2.4. Flow
Cytometry
18.9.3.1.2.5. Others
18.9.3.2. Egypt
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Technology
18.9.3.2.1. 2D
18.9.3.2.2. 3D
18.9.3.3. Egypt
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell Types
18.9.3.3.1. Natural
Killer Cells
18.9.3.3.2. Macrophages
18.9.3.3.3. Dendritic
Cells
18.9.3.3.4. Neutrophils
18.9.3.3.5. Fibroblasts
18.9.3.3.6. Others
18.9.3.4. Egypt
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Application
18.9.3.4.1. Screen
and Develop Antibodies
18.9.3.4.2. Small
Molecules
18.9.3.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
18.9.3.4.4. ADCC
18.9.3.4.5. ADCP
18.9.3.4.6. T
Cell Redirection
18.9.3.4.7. Adoptive
T Cell Therapy
18.9.3.4.8. Others
18.9.3.5. Egypt
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
18.9.3.5.1. PD-1
18.9.3.5.2. SIRP?
18.9.3.5.3. CTLA4
18.9.3.5.4. OX40
18.9.3.5.5. ICOS
18.9.3.5.6. Others
18.9.3.6. Egypt
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Indication
18.9.3.6.1. Lung
Cancer
18.9.3.6.2. Colorectal
Cancer
18.9.3.6.3. Melanoma
18.9.3.6.4. Bladder
Cancer
18.9.3.6.5. Other
Cancers
18.9.3.7. Egypt
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
18.9.3.7.1. Research
Solutions
18.9.3.7.1.1. Tumor
Microenvironment and Immune Composition
18.9.3.7.1.2. Tumor
Mutational Burden and Neoantigens
18.9.3.7.1.3. Cancer
Microbiome Research
18.9.3.7.1.4. Immunotherapy
Research Publications
18.9.3.7.1.5. Others
18.9.3.7.2. Others
18.9.4. Kuwait
18.9.4.1. Kuwait
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Component
18.9.4.1.1. Consumables
18.9.4.1.1.1. Cytotoxicity
Assays
18.9.4.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
18.9.4.1.1.3. Functional
Assays
18.9.4.1.1.4. Custom
18.9.4.1.1.5. Others
18.9.4.1.2. Software
Platform
18.9.4.1.2.1. Immunoassay
18.9.4.1.2.2. PCR
18.9.4.1.2.3. NGS
18.9.4.1.2.4. Flow
Cytometry
18.9.4.1.2.5. Others
18.9.4.2. Kuwait
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Technology
18.9.4.2.1. 2D
18.9.4.2.2. 3D
18.9.4.3. Kuwait
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell Types
18.9.4.3.1. Natural
Killer Cells
18.9.4.3.2. Macrophages
18.9.4.3.3. Dendritic
Cells
18.9.4.3.4. Neutrophils
18.9.4.3.5. Fibroblasts
18.9.4.3.6. Others
18.9.4.4. Kuwait
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Application
18.9.4.4.1. Screen
and Develop Antibodies
18.9.4.4.2. Small
Molecules
18.9.4.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
18.9.4.4.4. ADCC
18.9.4.4.5. ADCP
18.9.4.4.6. T
Cell Redirection
18.9.4.4.7. Adoptive
T Cell Therapy
18.9.4.4.8. Others
18.9.4.5. Kuwait
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
18.9.4.5.1. PD-1
18.9.4.5.2. SIRP?
18.9.4.5.3. CTLA4
18.9.4.5.4. OX40
18.9.4.5.5. ICOS
18.9.4.5.6. Others
18.9.4.6. Kuwait
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Indication
18.9.4.6.1. Lung
Cancer
18.9.4.6.2. Colorectal
Cancer
18.9.4.6.3. Melanoma
18.9.4.6.4. Bladder
Cancer
18.9.4.6.5. Other
Cancers
18.9.4.7. Kuwait
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
18.9.4.7.1. Research
Solutions
18.9.4.7.1.1. Tumor
Microenvironment and Immune Composition
18.9.4.7.1.2. Tumor
Mutational Burden and Neoantigens
18.9.4.7.1.3. Cancer
Microbiome Research
18.9.4.7.1.4. Immunotherapy
Research Publications
18.9.4.7.1.5. Others
18.9.4.7.2. Others
18.9.5. South
Africa
18.9.5.1. South
Africa Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Component
18.9.5.1.1. Consumables
18.9.5.1.1.1. Cytotoxicity
Assays
18.9.5.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
18.9.5.1.1.3. Functional
Assays
18.9.5.1.1.4. Custom
18.9.5.1.1.5. Others
18.9.5.1.2. Software
Platform
18.9.5.1.2.1. Immunoassay
18.9.5.1.2.2. PCR
18.9.5.1.2.3. NGS
18.9.5.1.2.4. Flow
Cytometry
18.9.5.1.2.5. Others
18.9.5.2. South
Africa Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Technology
18.9.5.2.1. 2D
18.9.5.2.2. 3D
18.9.5.3. South
Africa Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell
Types
18.9.5.3.1. Natural
Killer Cells
18.9.5.3.2. Macrophages
18.9.5.3.3. Dendritic
Cells
18.9.5.3.4. Neutrophils
18.9.5.3.5. Fibroblasts
18.9.5.3.6. Others
18.9.5.4. South
Africa Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Application
18.9.5.4.1. Screen
and Develop Antibodies
18.9.5.4.2. Small
Molecules
18.9.5.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
18.9.5.4.4. ADCC
18.9.5.4.5. ADCP
18.9.5.4.6. T
Cell Redirection
18.9.5.4.7. Adoptive
T Cell Therapy
18.9.5.4.8. Others
18.9.5.5. South
Africa Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
18.9.5.5.1. PD-1
18.9.5.5.2. SIRP?
18.9.5.5.3. CTLA4
18.9.5.5.4. OX40
18.9.5.5.5. ICOS
18.9.5.5.6. Others
18.9.5.6. South
Africa Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Indication
18.9.5.6.1. Lung
Cancer
18.9.5.6.2. Colorectal
Cancer
18.9.5.6.3. Melanoma
18.9.5.6.4. Bladder
Cancer
18.9.5.6.5. Other
Cancers
18.9.5.7. South
Africa Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
18.9.5.7.1. Research
Solutions
18.9.5.7.1.1. Tumor
Microenvironment and Immune Composition
18.9.5.7.1.2. Tumor
Mutational Burden and Neoantigens
18.9.5.7.1.3. Cancer
Microbiome Research
18.9.5.7.1.4. Immunotherapy
Research Publications
18.9.5.7.1.5. Others
18.9.5.7.2. Others
18.9.6. Rest of
Middle East & Africa
18.9.6.1. Rest
of Middle East & Africa Immuno Oncology Assays Market Revenue (US$ Mn) and
Forecasts, By Component
18.9.6.1.1. Consumables
18.9.6.1.1.1. Cytotoxicity
Assays
18.9.6.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
18.9.6.1.1.3. Functional
Assays
18.9.6.1.1.4. Custom
18.9.6.1.1.5. Others
18.9.6.1.2. Software
Platform
18.9.6.1.2.1. Immunoassay
18.9.6.1.2.2. PCR
18.9.6.1.2.3. NGS
18.9.6.1.2.4. Flow
Cytometry
18.9.6.1.2.5. Others
18.9.6.2. Rest
of Middle East & Africa Immuno Oncology Assays Market Revenue (US$ Mn) and
Forecasts, By Technology
18.9.6.2.1. 2D
18.9.6.2.2. 3D
18.9.6.3. Rest
of Middle East & Africa Immuno Oncology Assays Market Revenue (US$ Mn) and
Forecasts, By Cell Types
18.9.6.3.1. Natural
Killer Cells
18.9.6.3.2. Macrophages
18.9.6.3.3. Dendritic
Cells
18.9.6.3.4. Neutrophils
18.9.6.3.5. Fibroblasts
18.9.6.3.6. Others
18.9.6.4. Rest
of Middle East & Africa Immuno Oncology Assays Market Revenue (US$ Mn) and
Forecasts, By Application
18.9.6.4.1. Screen
and Develop Antibodies
18.9.6.4.2. Small
Molecules
18.9.6.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
18.9.6.4.4. ADCC
18.9.6.4.5. ADCP
18.9.6.4.6. T
Cell Redirection
18.9.6.4.7. Adoptive
T Cell Therapy
18.9.6.4.8. Others
18.9.6.5. Rest
of Middle East & Africa Immuno Oncology Assays Market Revenue (US$ Mn) and
Forecasts, By Targets
18.9.6.5.1. PD-1
18.9.6.5.2. SIRP?
18.9.6.5.3. CTLA4
18.9.6.5.4. OX40
18.9.6.5.5. ICOS
18.9.6.5.6. Others
18.9.6.6. Rest
of Middle East & Africa Immuno Oncology Assays Market Revenue (US$ Mn) and
Forecasts, By Indication
18.9.6.6.1. Lung
Cancer
18.9.6.6.2. Colorectal
Cancer
18.9.6.6.3. Melanoma
18.9.6.6.4. Bladder
Cancer
18.9.6.6.5. Other
Cancers
18.9.6.7. Rest
of Middle East & Africa Immuno Oncology Assays Market Revenue (US$ Mn) and
Forecasts, By Usage
18.9.6.7.1. Research
Solutions
18.9.6.7.1.1. Tumor
Microenvironment and Immune Composition
18.9.6.7.1.2. Tumor
Mutational Burden and Neoantigens
18.9.6.7.1.3. Cancer
Microbiome Research
18.9.6.7.1.4. Immunotherapy
Research Publications
18.9.6.7.1.5. Others
18.9.6.7.2. Others
18.10. Key
Segment for Channeling Investments
18.10.1. By
Country
18.10.2. By
Component
18.10.3. By
Technology
18.10.4. By
Cell Types
18.10.5. By
Application
18.10.6. By
Targets
18.10.7. By
Indication
18.10.8. By
Usage
19. Latin
America Immuno Oncology Assays Market Analysis and Forecasts, 2020 - 2028
19.1. Overview
19.1.1. Latin
America Immuno Oncology Assays Market Revenue (US$ Mn)
19.2. Latin
America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Component
19.2.1. Consumables
19.2.1.1. Cytotoxicity
Assays
19.2.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
19.2.1.3. Functional
Assays
19.2.1.4. Custom
19.2.1.5. Others
19.2.2. Software
Platform
19.2.2.1. Immunoassay
19.2.2.2. PCR
19.2.2.3. NGS
19.2.2.4. Flow
Cytometry
19.2.2.5. Others
19.3. Latin
America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Technology
19.3.1. 2D
19.3.2. 3D
19.4. Latin
America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell
Types
19.4.1. Natural
Killer Cells
19.4.2. Macrophages
19.4.3. Dendritic
Cells
19.4.4. Neutrophils
19.4.5. Fibroblasts
19.4.6. Others
19.5. Latin
America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Application
19.5.1. Screen
and Develop Antibodies
19.5.2. Small
Molecules
19.5.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
19.5.4. ADCC
19.5.5. ADCP
19.5.6. T Cell
Redirection
19.5.7. Adoptive
T Cell Therapy
19.5.8. Others
19.6. Latin America
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
19.6.1. PD-1
19.6.2. SIRP?
19.6.3. CTLA4
19.6.4. OX40
19.6.5. ICOS
19.6.6. Others
19.7. Latin
America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Indication
19.7.1. Lung
Cancer
19.7.2. Colorectal
Cancer
19.7.3. Melanoma
19.7.4. Bladder
Cancer
19.7.5. Other
Cancers
19.8. Latin
America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
19.8.1. Research
Solutions
19.8.1.1. Tumor
Microenvironment and Immune Composition
19.8.1.2. Tumor
Mutational Burden and Neoantigens
19.8.1.3. Cancer
Microbiome Research
19.8.1.4. Immunotherapy
Research Publications
19.8.1.5. Others
19.8.2. Others
19.9. Latin
America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By
Country
19.9.1. Brazil
19.9.1.1. Brazil
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Component
19.9.1.1.1. Consumables
19.9.1.1.1.1. Cytotoxicity
Assays
19.9.1.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
19.9.1.1.1.3. Functional
Assays
19.9.1.1.1.4. Custom
19.9.1.1.1.5. Others
19.9.1.1.2. Software
Platform
19.9.1.1.2.1. Immunoassay
19.9.1.1.2.2. PCR
19.9.1.1.2.3. NGS
19.9.1.1.2.4. Flow
Cytometry
19.9.1.1.2.5. Others
19.9.1.2. Brazil
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Technology
19.9.1.2.1. 2D
19.9.1.2.2. 3D
19.9.1.3. Brazil
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell Types
19.9.1.3.1. Natural
Killer Cells
19.9.1.3.2. Macrophages
19.9.1.3.3. Dendritic
Cells
19.9.1.3.4. Neutrophils
19.9.1.3.5. Fibroblasts
19.9.1.3.6. Others
19.9.1.4. Brazil
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Application
19.9.1.4.1. Screen
and Develop Antibodies
19.9.1.4.2. Small
Molecules
19.9.1.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
19.9.1.4.4. ADCC
19.9.1.4.5. ADCP
19.9.1.4.6. T
Cell Redirection
19.9.1.4.7. Adoptive
T Cell Therapy
19.9.1.4.8. Others
19.9.1.5. Brazil
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
19.9.1.5.1. PD-1
19.9.1.5.2. SIRP?
19.9.1.5.3. CTLA4
19.9.1.5.4. OX40
19.9.1.5.5. ICOS
19.9.1.5.6. Others
19.9.1.6. Brazil
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Indication
19.9.1.6.1. Lung
Cancer
19.9.1.6.2. Colorectal
Cancer
19.9.1.6.3. Melanoma
19.9.1.6.4. Bladder
Cancer
19.9.1.6.5. Other
Cancers
19.9.1.7. Brazil
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
19.9.1.7.1. Research
Solutions
19.9.1.7.1.1. Tumor
Microenvironment and Immune Composition
19.9.1.7.1.2. Tumor
Mutational Burden and Neoantigens
19.9.1.7.1.3. Cancer
Microbiome Research
19.9.1.7.1.4. Immunotherapy
Research Publications
19.9.1.7.1.5. Others
19.9.1.7.2. Others
19.9.2. Argentina
19.9.2.1. Argentina
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Component
19.9.2.1.1. Consumables
19.9.2.1.1.1. Cytotoxicity
Assays
19.9.2.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
19.9.2.1.1.3. Functional
Assays
19.9.2.1.1.4. Custom
19.9.2.1.1.5. Others
19.9.2.1.2. Software
Platform
19.9.2.1.2.1. Immunoassay
19.9.2.1.2.2. PCR
19.9.2.1.2.3. NGS
19.9.2.1.2.4. Flow
Cytometry
19.9.2.1.2.5. Others
19.9.2.2. Argentina
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Technology
19.9.2.2.1. 2D
19.9.2.2.2. 3D
19.9.2.3. Argentina
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Cell Types
19.9.2.3.1. Natural
Killer Cells
19.9.2.3.2. Macrophages
19.9.2.3.3. Dendritic
Cells
19.9.2.3.4. Neutrophils
19.9.2.3.5. Fibroblasts
19.9.2.3.6. Others
19.9.2.4. Argentina
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Application
19.9.2.4.1. Screen
and Develop Antibodies
19.9.2.4.2. Small
Molecules
19.9.2.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
19.9.2.4.4. ADCC
19.9.2.4.5. ADCP
19.9.2.4.6. T
Cell Redirection
19.9.2.4.7. Adoptive
T Cell Therapy
19.9.2.4.8. Others
19.9.2.5. Argentina
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Targets
19.9.2.5.1. PD-1
19.9.2.5.2. SIRP?
19.9.2.5.3. CTLA4
19.9.2.5.4. OX40
19.9.2.5.5. ICOS
19.9.2.5.6. Others
19.9.2.6. Argentina
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Indication
19.9.2.6.1. Lung
Cancer
19.9.2.6.2. Colorectal
Cancer
19.9.2.6.3. Melanoma
19.9.2.6.4. Bladder
Cancer
19.9.2.6.5. Other
Cancers
19.9.2.7. Argentina
Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts, By Usage
19.9.2.7.1. Research
Solutions
19.9.2.7.1.1. Tumor
Microenvironment and Immune Composition
19.9.2.7.1.2. Tumor
Mutational Burden and Neoantigens
19.9.2.7.1.3. Cancer
Microbiome Research
19.9.2.7.1.4. Immunotherapy
Research Publications
19.9.2.7.1.5. Others
19.9.2.7.2. Others
19.9.3. Rest of
Latin America
19.9.3.1. Rest
of Latin America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Component
19.9.3.1.1. Consumables
19.9.3.1.1.1. Cytotoxicity
Assays
19.9.3.1.1.2. MOA-Reflective
Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
19.9.3.1.1.3. Functional
Assays
19.9.3.1.1.4. Custom
19.9.3.1.1.5. Others
19.9.3.1.2. Software
Platform
19.9.3.1.2.1. Immunoassay
19.9.3.1.2.2. PCR
19.9.3.1.2.3. NGS
19.9.3.1.2.4. Flow
Cytometry
19.9.3.1.2.5. Others
19.9.3.2. Rest
of Latin America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Technology
19.9.3.2.1. 2D
19.9.3.2.2. 3D
19.9.3.3. Rest
of Latin America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Cell Types
19.9.3.3.1. Natural
Killer Cells
19.9.3.3.2. Macrophages
19.9.3.3.3. Dendritic
Cells
19.9.3.3.4. Neutrophils
19.9.3.3.5. Fibroblasts
19.9.3.3.6. Others
19.9.3.4. Rest
of Latin America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Application
19.9.3.4.1. Screen
and Develop Antibodies
19.9.3.4.2. Small
Molecules
19.9.3.4.3. Cellular
Therapies (Chimeric Antigen Receptor T Cells (CAR-T)
19.9.3.4.4. ADCC
19.9.3.4.5. ADCP
19.9.3.4.6. T
Cell Redirection
19.9.3.4.7. Adoptive
T Cell Therapy
19.9.3.4.8. Others
19.9.3.5. Rest
of Latin America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Targets
19.9.3.5.1. PD-1
19.9.3.5.2. SIRP?
19.9.3.5.3. CTLA4
19.9.3.5.4. OX40
19.9.3.5.5. ICOS
19.9.3.5.6. Others
19.9.3.6. Rest
of Latin America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Indication
19.9.3.6.1. Lung
Cancer
19.9.3.6.2. Colorectal
Cancer
19.9.3.6.3. Melanoma
19.9.3.6.4. Bladder
Cancer
19.9.3.6.5. Other
Cancers
19.9.3.7. Rest
of Latin America Immuno Oncology Assays Market Revenue (US$ Mn) and Forecasts,
By Usage
19.9.3.7.1. Research
Solutions
19.9.3.7.1.1. Tumor
Microenvironment and Immune Composition
19.9.3.7.1.2. Tumor
Mutational Burden and Neoantigens
19.9.3.7.1.3. Cancer
Microbiome Research
19.9.3.7.1.4. Immunotherapy
Research Publications
19.9.3.7.1.5. Others
19.9.3.7.2. Others
19.10. Key
Segment for Channeling Investments
19.10.1. By
Country
19.10.2. By
Component
19.10.3. By
Technology
19.10.4. By
Cell Types
19.10.5. By Application
19.10.6. By
Targets
19.10.7. By
Indication
19.10.8. By
Usage
20. Competitive
Benchmarking
20.1. Market
Share Analysis, 2019
20.2. Global
Presence and Growth Strategies
20.2.1. Mergers
and Acquisitions
20.2.2. Product
Launches
20.2.3. Investments
Trends
20.2.4. R&D
Initiatives
21. Player
Profiles
21.1. Agilent
21.1.1. Company
Details
21.1.2. Company
Overview
21.1.3. Product
Offerings
21.1.4. Key
Developments
21.1.5. Financial
Analysis
21.1.6. SWOT
Analysis
21.1.7. Business
Strategies
21.2. BioAgilytix
21.2.1. Company
Details
21.2.2. Company
Overview
21.2.3. Product
Offerings
21.2.4. Key
Developments
21.2.5. Financial
Analysis
21.2.6. SWOT
Analysis
21.2.7. Business
Strategies
21.3. Charles
River Laboratories
21.3.1. Company
Details
21.3.2. Company
Overview
21.3.3. Product
Offerings
21.3.4. Key
Developments
21.3.5. Financial
Analysis
21.3.6. SWOT
Analysis
21.3.7. Business
Strategies
21.4. Creative
Biolabs
21.4.1. Company
Details
21.4.2. Company
Overview
21.4.3. Product
Offerings
21.4.4. Key
Developments
21.4.5. Financial
Analysis
21.4.6. SWOT
Analysis
21.4.7. Business
Strategies
21.5. Eurofins
DiscoverX Products
21.5.1. Company
Details
21.5.2. Company
Overview
21.5.3. Product
Offerings
21.5.4. Key
Developments
21.5.5. Financial
Analysis
21.5.6. SWOT
Analysis
21.5.7. Business
Strategies
21.6. Explicyte
Immuno-Oncology
21.6.1. Company
Details
21.6.2. Company
Overview
21.6.3. Product
Offerings
21.6.4. Key Developments
21.6.5. Financial
Analysis
21.6.6. SWOT
Analysis
21.6.7. Business
Strategies
21.7. Illumina,
Inc.
21.7.1. Company
Details
21.7.2. Company
Overview
21.7.3. Product
Offerings
21.7.4. Key
Developments
21.7.5. Financial
Analysis
21.7.6. SWOT
Analysis
21.7.7. Business
Strategies
21.8. Svar Life
Science
21.8.1. Company
Details
21.8.2. Company
Overview
21.8.3. Product
Offerings
21.8.4. Key
Developments
21.8.5. Financial
Analysis
21.8.6. SWOT
Analysis
21.8.7. Business
Strategies
21.9. Thermo
Fisher Scientific
21.9.1. Company
Details
21.9.2. Company
Overview
21.9.3. Product
Offerings
21.9.4. Key
Developments
21.9.5. Financial
Analysis
21.9.6. SWOT
Analysis
21.9.7. Business Strategies
21.10. Other
Industry Participants
22. Key
Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.